+

WO1986002383A1 - Antigenes d'enveloppe du virus des lymphadenopathies et leurs applications - Google Patents

Antigenes d'enveloppe du virus des lymphadenopathies et leurs applications Download PDF

Info

Publication number
WO1986002383A1
WO1986002383A1 PCT/EP1985/000548 EP8500548W WO8602383A1 WO 1986002383 A1 WO1986002383 A1 WO 1986002383A1 EP 8500548 W EP8500548 W EP 8500548W WO 8602383 A1 WO8602383 A1 WO 8602383A1
Authority
WO
WIPO (PCT)
Prior art keywords
glu
asn
gln
arg
ser
Prior art date
Application number
PCT/EP1985/000548
Other languages
English (en)
Inventor
Luc Montagnier
Bernard Krust
Solange Chamaret
François Clavel
Jean-Claude Chermann
Françoise Barre-Sinoussi
Marc Alizon
Pierre Sonigo
Cole Stewart
Olivier Danos
Simon Wain-Hobson
Original Assignee
Institut Pasteur
Centre National De La Recherche Scientifique
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27251244&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO1986002383(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from FR8416013A external-priority patent/FR2571968B1/fr
Priority claimed from GB848429099A external-priority patent/GB8429099D0/en
Priority claimed from GB858501473A external-priority patent/GB8501473D0/en
Application filed by Institut Pasteur, Centre National De La Recherche Scientifique filed Critical Institut Pasteur
Priority to KR1019860700374A priority Critical patent/KR930000189B1/ko
Priority to AT85905513T priority patent/ATE64601T1/de
Priority to DE8585905513T priority patent/DE3583293D1/de
Priority to EP85905513A priority patent/EP0201540B2/fr
Publication of WO1986002383A1 publication Critical patent/WO1986002383A1/fr
Priority to DK198602849A priority patent/DK174910B1/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1054—Lentiviridae, e.g. HIV, FIV, SIV gag-pol, e.g. p17, p24
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/702—Specific hybridization probes for retroviruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/702—Specific hybridization probes for retroviruses
    • C12Q1/703—Viruses associated with AIDS
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Definitions

  • the present invention relates to antigens, particularly in a purified form, of the virus of lymphadenopathies (denoted below by the abbreviation LAS) and of the acquired immuno-depressive syndrome (denoted below by the abbreviation AIDS), to a process for producing these antigens, particularly antigens of the envelopes of these viruses.
  • the invention also relates to polypeptides, whether glycosylated or not, encoded by said DNA sequences.
  • the causative agent if LAS or AIDS, a retrovirus has been identified by F. BARRE-SINOUSSI et al, Science, 220, 868. (1983). It has the following characteristics. It is T-lymphotropic; its prefered target is constituted by Leu 3 cells (or T4 lymphocytes) ; it has reverse transcriptase activity necessitating the presence of Mg + and exhibits strong affinity for poly(adenylate-oligodeoxy-thymidylate)(poly(A)-oligo(dT)12-18). It has a density of 1.16-1.17 in a sucrose gradient, an average diameter of 139 nanometers; and a nucleus having an average diameter of 41 nanometers.
  • Antigens of said virus are recognised immunologically by antibodies contained in serums taken up from patients afflicted with LAS or AIDS.
  • the p25 protein which is a core protein, is not recognised immunologically by the p24 protein of the HTLVI and II viruses.
  • the virus is also free of a p19 protein which is immunologicailly cross-reactive with the p19 proteins of HTLVI and HTLVII.
  • Retroviruses of this type (sometimes denoted by the generic abbreviation LAV) have been filed in the National Collection of Micro-organism Cultures of the INSTITUT PASTEUR of Paris, under numbers 1-232, 1-240 and 1-241.
  • Virus strains similar to LAV in all respects from the morphological and immunological point of view have been isolated in other laboratories. Reference is made by way of examples to the retrovirus strains named HTLV-III isolated by R.C. GALLO et al., Science, 224, 500 (1984) and by M.G. SARNGADHARAN et al., Science 224, 506 (1984) respectively and to the retrovirus isolated by M. JAY LEVY et al., Science, 225, 840-842 (1984), which virus was designated ARV. For the ease of language the last mentioned viruses, as well as others which have equivalent morphological and immunological properties, will be designated hereafter under the generic designation "LAV”. Reference is also made to European patent application filed 14 September 1984, with the priority of British patent application number 83 24800. filed 15 September 1983 as regards a more detailed description of the LAV retroviruses or the like and of the uses to which extracts of these viruses give rise.
  • the core antigens were the main antigens of the virus lysates or extracts which were recognised by serums of patients infected with AIDS or LAS, in the test systems which had then been used.
  • a p42 protein presented as consisting of an envelope protein, had been detected too.
  • GALLO et al disclosed a p41 protein which was also deemed to be on a possible component of the viru envelope.
  • - culturing cells infected with TCGF, in the presence of anti- ⁇ -interferon sheep serum - effecting purification of the virus produced (production starts generally between the 9th and the 15th day following infection and lasts from 10 to 15 days), which purification comprises precipitating the virus in polyethylenglycol in order to produce a first concentration of the virus, then centrifugating the preparation obtained in a 20-60 % sucrose gradient or in an isotonic gradient of metrizanide (sold under the trade mark NYCODENZ by NYEGAARD, Oslo) and recovering the virus with the band having a density of 1.16-1.17 in the sucrose gradient or of 1.10-1.11 in the NYCODENZ gradient.
  • purification comprises precipitating the virus in polyethylenglycol in order to produce a first concentration of the virus, then centrifugating the preparation obtained in a 20-60 % sucrose gradient or in an isotonic gradient of metrizanide (sold under the trade mark NYCODENZ by NYEGA
  • the LAV virus may also be produced from permanent cell lines of type T, such as the CEM line, or from B lymphoblastoid cell lines, such as obtained by the transformation of the lymphocytes derived from a healthy donor with the Epstein-Barr virus, for instance as disclosed in French patent application Nr. 84 07151 filed May 9, 1984.
  • the permanent cell lines obtained produce continuously a virus (designated as LAV-B in the case of the B lymphoblastoid cell lines) which possesses the essential antigenic and morphological features of the LAV viruses (except that it is collected in a density band sometimes slightly higher than in the preceding case (particularly 1.18) in sucrose.
  • the final purification of the virus can also be carried out in a NYCODENZ gradient.
  • the invention aims at providing purified unaltered virus forms (or viruses less altered by the purification procedures resorted to) and processes for obtaining said unaltered purified viruses.
  • the present invention further aims at providing additional new means which should not only also be useful for the detection of LAV or related viruses (hereafter more generally referred to as "LAV viruses"), but also have more versatility, particularly in detecting specific parts of the genomic DNA of said viruses whose expression products are not always directly detectable by immunological methods.
  • the present invention further aims at providing polypeptides containing sequences in common with polypeptides comprising antigenic determinants included in the proteins encoded and expressed by the LAV genome occuring in nature.
  • An additional object of the invention is to further provide means for the detection of proteins related to LAV virus, particularly for the diagnosis of AIDS or pre-AIDS or, to the contrary, for the detection of antibodies against the LAV virus or proteins related therewith, particularly in patients afflicted with AIDS or pre-AIDS or more generally in asymtomatic carriers and in blood-related products.
  • the invention also aims at providing immunogenic polypeptides, and more particularly protective polypeptides for use in the preparation of vaccine compositions against AIDS or related syndroms.
  • the present invention relates to additional DNA. fragments, hybridizable with the genomic RNA of LAV as they will be disclosed hereafter, as well as with additional cDNA variants corresponding to the whole genomes of LAV viruses. It further relates to DNA recombinants containing said DNAs or cDNA fragments.
  • An unaltered purified LAV retrovirus distinguishes from those which have been defined above, in that it includes an amount of one or several envelope antigens, sufficient to be visualized when the virus is labelled with 35 S-cystein, free of unlabelled cystein in a proportion of 200 microcuries per ml of medium, these antigens, among which particularly glycoproteins, are recognised selectively in vitro by serums of patients affected with SIDA or SLAs or by the serums of asymptomatic carriers of the virus.
  • a preferred antigen according to the preceding definition obtainable from a lysate of this virus (or by gentle scouring of the envelopes of the virus) is a glycoprotein having a molecular weight of the order of 110,000 daltons, as determined by its migration distance in comparison with the distances of migrations, in a same migration system, of standard proteins having known molecular weights. Particularly comparative measurements were made on a 12.5 % polyacrylamid gel under a voltage of 18 V for 18 hours, upon using the following standard proteins (marketed by AMERSHAM) :
  • the invention relates also to the antigens themselves, particularly that of molecular weight of about 110,000-120,000, which possess also the capability of being recognised by serums of patients infected with AIDS or LAS or by serums of persons who have been exposed to LAV viruses or those analogous with the latter.
  • These antigens have also the characteristic of forming complexes with concanavaline A, said complex being dissociatable in the presence of O-methyl- ⁇ -D-mannopyranoside.
  • the antigens according to the invention can also bind to other lectins for example those known under the name "LENTYL-LECTIN".
  • the preferred antigen according to the invention, of molecular weight 110,000 is also sensitive to the action of endoglycosidases.
  • This action is manifested by the production from the antigen of molecular weight 110,000 of a protein having a molecular weight of the order of 90,000, the latter being separable for example by immunoprecipitation or by separation employing the differences in molecular weights (migrations differentiated on gel).
  • Preferred antigens of the invention are constituted by glycoproteins.
  • the invention relates also to the process for producing the viruses according to the invention. This process distinguishes essentially from those recalled above at the level of the final purification operation.
  • the purification step of the process according to the invention is no longer carried out in gradients, but involves the performance of differential centrifugations effected directly on the supernatants of the culture media of the producing cells.
  • centrifugation operations comprise, particularly a first centrifugation at an angular centrifugation velocity, particularly of 10,000 rpm, enabling the removal of nonviral constituents, more particularly of cellular constituents, then a second centrifugation at higher angular velocity, particularly at 45,000 rpm, to obtain the precipitation of the virus itself.
  • the first centrifugation at 10,000 rpm is maintained for 10 minutes and the second at 45,000 rpm, for 20 minutes.
  • This modification of the purification process results in the production of viral preparaations from which the antigen mentioned can then be isolated more easely, than from virus preparations purified by the previous methods.
  • the viruses finally obtained by the process of the present invention are more easely recognised by serums of patients or of persons who have been exposed to the LAV virus or to morphologically and antigenically similar strains.
  • the antigens according to the invention can themselve be obtained from the above disclosed viruses, by lysis (or other suitable processing) of the latter in the presence of any suitable detergent and by recovery and separation of the antigens released.
  • the lysis of the virus is effected in the presence of aprotinin or of any other agent suitable for inhibiting the action of proteases.
  • the separation of the antigens according to the invention can then be carried out by any method known in itself ; for example, it is possible to proceed with a separation of the proteins by employing their respectively different migrations in a predetermined gel, the protein sought being then isolated from the zone of the gel in which it would normally be found in an electrophoresis operation under well determined conditions, having regard to its molecular weight.
  • the antigens according to the invention can however be separated from the lysate of the abovesaid viruses, due tb their affinity for lectins, in particular concanavaline A or lentyl-lectin.
  • the lectin used is preferably immobilised on a solid support, such as the cross linked polymer derived from agarose and marketed under the trade mark SEPHAROSE. After washing of the fixed antigens with a suitable buffer, the antigens can be eluted in any suitable manner, particularly by resorting to a O-methyl-o-Dmannopyranoside in solution.
  • a more thorough purification of these antigens can be performed by immunoprecipitation with the serums of patients known to possess antibodies effective against said protein, with concentrated antibody preparations (polyclonal antibodies) or again with monoclonal antibodies, more particularly directed against the antigen according to the invention, in particular that having the molecular weight of 110,000, denoted below by the abbreviation gp110.
  • Figure 1 is derived from a photographic reproduction of gel strips which have been used to carry out electrophoreses of lysate extracts of T lymphocytes, respectively infected and uninfected (controls) by a LAV suspension.
  • Figure 2 is the restriction map of a complete LAV genome (clone ⁇ J19).
  • Figures 3a to 3e are the complete sequence of a LAV viral genome.
  • FIGs 4 and 5 show diagrammatically parts of the three possible reading phases of LAV genomic RNA, including the open reading frames (ORF) apparent in each of said reading phases.
  • Figure 6 is a schematic representation of the LAV long terminal repeat (LTR).
  • the supernatant liquor from the culture medium was then subjected to a first centrifugation at 10,000 rpm for 10 minutes to remove the non viral components, then to a second centrifugation at 45,000 rpm for 20 minutes for sedimenting the virus, the virus pellet was then lysed by detergent in the presence of aprotinin (5 %) particularly under the conditions described in the article of F. BARRE-SINOUSSI et Coll.
  • lymphocytes taken up from a healthy donor as control The same operation was repeated on lymphocytes taken up from a healthy donor as control.
  • the various lysates were then immuno-precipitated by serums of patients infected with AIDS or with LAS. Serums originating from healthy donors or of donors infected with other diseases were immunoprecipitated too. The media were then subjected to electrophoreses in a SDS-polyacrylamide gel.
  • strip M corresponds to the migration distances of the standard proteins identified above, whose molecular weights are recalled in the right hand portion of the figure.
  • the virus according to the invention and the antigen according to the invention can be either precipitated by lectins, particularly concanavaline A, or fixed to a SEPHAROSE-concanavaline A column.
  • lectins particularly concanavaline A
  • SEPHAROSE-concanavaline A column Particularly the purification of the envelope glycoproteins can be carried out as follows. This fixation can particularly be carried out by contacting a lysate of the LAV virus dissolved in a suitable buffer with concanavaline-A bound to SEPHAROSE.
  • a suitable buffer has the following composition :
  • SEPHAROSE-concanavaline A is washed with a buffer of the same composition, except that the TRITON concentration is lowered to 0.1 % . The elution is then effected with an 0.2 M O-methyl- ⁇ -D-mannopyranoside solution in the washing buffer.
  • the protein may be further concentrated by immuno-precipitation with antibodies contained in the serums of patients infected with AIDS or with polyclonal antibodies obtained from a serum derived from an animal previously immunised against the "unaltered" virus according to the invention or the abovesaid glycoprotein.
  • the protein can then be recovered by dissociation of the complex by a solution having an adequate content of ionic salt.
  • the antibody preparation is itself immobilised in a manner known in itself on an insoluble support, for instance of the SEPHAROSE B type.
  • mice A technique for producing and selecting monoclonal antibodies directed against the gp110 glycoprotein is described below . Immunisation of the mice
  • mice Groups of Balb/c mice from 6 to 8 weeks old mice were used. One group receives the virus carrying the abovesaid glycoprotein, another a purified glycoprotein gp110.
  • the immunisation procedure identical for all mice, comprises injecting 10 mg of the antigenic preparation in the prsence of Freund complete adjuvant at day 0, then again but in the presence of Freund incomplete adjuvant at day 14 and without adjuvant at days 28 and 42. The three first injections are made intraperitoneally, the fourth intravenously. Fusion and culture of the hybrids
  • the non secreting myeloma variant 5.53 P3 x 63 Ag8, resistant to azaguanine, itself derived from the MOPC-21 cell-line, is used.
  • Fusion with immunised mouse splenocytes is carried out in the presence of polyethylene-glycol 4000 by the technique of FAZEKAS de st-GROTH and SCHEIDEGGER on the 45th day.
  • the selection of the hybrids in RPMI 16-40 "HAT" medium is carried out in plates having 24 cups (known under the designation COSTAR) by resorting to the same culture techniques.
  • the hybridomas producing antibodies of adequate specificity are then cloned in plates having 96 cups, in the presence of a "feeder" layer of syngenic thymocytes.
  • the producing clones thus selected are then expanded in 24 cup plates, still in the presence of thymocytes.
  • the clone is injected intraperitoneally into a balb/c mouse which had received an injection of PRISTANE 8 days previously and/or kept in liquid culture. Demonstration of the anti-LAV antibodies
  • the hybrids producing antibodies are determined by an ELISA test revealing mouse immunoglobulins in the supernatant liquors. From this first selection, supernatants are sought which have antibodies directed against viral constituents by means of an ELISA test revealing anti-LAV antibodies, or by immunofluorescence on the virus producing human cells. Finally the supernatant liquours are analysed by radioimmunoprecipitation of virus labelled with cystein and by the Western-Blot technique on viral preparation which permit the determination of the specificities of these anti-LAV antibodies.
  • Cells obtained from the various fusions are placed under culture in 648 cups. Their microscopic examination shows that the majority of these cups contain, a single hybrid clone capable of growing in a "HAT" selective medium. More than 50 % among them produce antibodies giving rise to a positive response under ELISA antivirus examination. The most representative fusions are tested by the Western-Blot technique and several of them are subcloned, taking into account their respective specificities reactivities in antivirus ELISA and their behaviours under the culturing conditions. Those hybrids which are more particularly selected are those which produce antibodies which selectively recognise the viral glycoprotein gp110 having a molecular weight of about 110 KD.
  • the monoclonal antibodies obtained can themselves be employed to purify proteins containing an antigenic site also contained in gp110.
  • the invention relates therefore also to these processes of purification as such.
  • This process is advantageously applied to virus lysates or T lymphocyte lysates or other cells producing LAV or the like, when care has been taken to avoid the uncontrolled separation of gp110 during the purification procedure of the virus, prior to lysys thereof.
  • the process can also be applied to any solution containing gp110 or a protein, polypeptide or glycoprotein comprising an antigenic site normally carried by the envelope protein and recognised by the monoclonal antibody.
  • the monoclonal antibodies are advantageously immobilised on a solid support, preferably adapted to affinity chromatography operations.
  • these monoclonal antibodies are fixed to an agarose lattice with threedimensional cross-linking, marketed under the trade mark SEPHAROSE by the Swedish company PHARMACIA A.G., for example by the cyanogen bromide method.
  • the invention therefore also relates to a process for separating the antigens concerned, which process comprises contacting a mixture of antigens, ineluding those of interest (for instance a virus lysate or extract), with an affinity column bearing the abovesaid monoclonal antibodies, to selectively fix polypeptides, proteins or glycoproteins selectively recognized by said monoclonal antibodies, recovering the latter by dissociation of the antigen-antibody complex by means of a suitable buffer, particularly a solution of adequate ionic strength, for example of a salt, preferably ammonium acetate (which leaves no residue upon freeze drying of the preparation or a solution acidified to a pH 2-4 or to a glycine buffer at the same pH and recovering the eluted polypeptides, proteins or glycoproteins.
  • a suitable buffer particularly a solution of adequate ionic strength, for example of a salt, preferably ammonium acetate (which leaves no residue upon freeze drying of the preparation or a solution acidified to a pH 2-4 or to
  • the invention relates also to polypeptide fragments having lower molecular weights and carrying antigenic sites recognizable by the same monoclonal antibodies. It is clear to the specialist that the availabililty of monoclonal antibodies recognizing the gp110 glycoprotein gives also access to smaller peptide sequences or fragments containing the common antigenic site or epitope. Fragments of smaller sizes may be obtained by resorting to known techniques. For instance such a method comprises cleaving the original larger polypeptide by enzymes capable of cleaving it at specific sites.
  • Such proteins may be mentioned the enzyme of Staphylococcvus aureus V8, ⁇ -chymotrypsine, "mouse sub-maxillary gland protease” marketed by the BOEHRINGER company, Vibrio al ⁇ inolvticus chemovar iophagus collagenase, which specifically recognises said peptides Gly-Pro and Gly-Ala, etc.. It is also possible to obtain polypeptides or fragments of envelope antigens of the virus, by cloning fragments excised from a cDNA constructed from genoimes of LAV variants,
  • Figures 2 and 3 are restriction maps of such a cDNA comprising a total of 9.1 to 9.2 kb.
  • the presence of a characteristic site of an envelope antigen of the LAV virus or the like in any polypeptide expressed can be detected by any suitable immunochemical means.
  • the invention relates more particularly to polypeptides encoded by cDNA fragments defined hereafter. It also relates to the nucleic acid fragments themselves, including a cDNA variant corresponding to a whole LAV retroviral genome, characterized by a series of restriction sites in the order hereafter (from the 5' end to the 3' end).
  • the coordinates of the successive sites of the whole LAV genome are indicated hereafter too, with respect to the Hind III site (selected as of coordinate 1) which is located in the R region.
  • the coordinates are estimated with an accuracy of ⁇ 200 bp :
  • Another DNA variant according to this invention ionally contains an additional Hind III approximately at the 5 550 coordinate.
  • the invention further relates to other preferred DNA fragments and polypeptide sequences (glycosylated or not glycosylated) which will be referred to hereafter.
  • Resuspended DNA in 10 mM Tris, pH 8 ; 0,1 mM EDTA was ligated into M13mp8 RF DNA (cut by the restriction enzyme Smal and subsequently alkaline phosphated), using T4 DNAand RNA-ligases (Maniatis T et al (1982) - Molecular cloning - Cold Spring Harbor Laboratory).
  • An E. coli strain designated as TG1 was used for further study. This strain has the following genotype : ⁇ lac pro, supE, thi. F' traD36, proAB, lacl q , Z ⁇ Ml5,r-
  • This E. coli TGI strain has the peculiarity of enabling recombmants to be recognized easily.
  • the blue colour of the cells transfected with plasmids which did not recombine with a fragment of LAV DNA is not modified.
  • cells transfected by a recombinant plasmid containing a LAV DNA fragment yield white colonies.
  • the technique which was used is disclosed in Gene (1983), 26, 101.
  • ⁇ J19 also designated as LAV-Ia
  • LAV-Ia The complete DNA sequence of ⁇ J19 (also designated as LAV-Ia) is shown in figs. 4 to 4e.
  • the sequence was reconstructed from the sequence of phage ⁇ J19 insert. The numbering starts at the cap site which was located experimentally (see hereafter). Important genetic elements, major open reading frames and their predicted products are indicated together with the HindiII cloning sites. The potential glycosylation sites in the env gene are overlined. The NH 2 -terminal sequence of p25 gag determined by protein microsequencing is boxed.
  • Each nucleotide was sequenced on average 5.3 times : 85 % of the sequence was determined on both strands and the remainder sequenced at least twice from independent clones.
  • the base composition is T, 22.2 % ; C, 17.8 % ; A, 35.8 % ; G, 244.2 % . G + C, 42 % .
  • the dinucleotide GC is greatly under represented (0,9 % ) as common amongst eukaryotic sequences (Bird 1980).
  • Figs. 5 and 6 provide a diagrammatized representation of the lengths of the successive open reading frames corresponding to the successive reading phases (also referred to by numbers “1", “2” and “3" appearing in the left handside part of fig. 5).
  • the relative positions of these open reading frames (ORF) with respect to the nucleotidic structure of the LAV genome is referred to by the scale of numbers representative of the respective positions of the corresponding nucleotides in the DNA sequence.
  • the vertical bars correspond to the positions of the corresponding stop codons.
  • the "gag gene” codes for core proteins. ⁇ ag : near the 5' extremity of the gag orf is a "typical" initiation codon (Kozak 1984) (position 336) which is not only the first in the gag orf, but the first from the cap site.
  • the N-terminal aminoacid sequence of the major core protein p25 is encoded by the nucleotide sequence starting from position 732 (fig. 5a). This formally makes the link between the cloned LAV genome and the immunologically characterized LAV p25 protein.
  • the protein encoded 5' of the p25 coding sequence is rather hydrophilie. Its calculated MW of 14866 is consistent with that of the gag protein p18.
  • the 3' "part of the gag region codes probably for the retroviral nucleic acid binding protein (NBP). Indeed, like in HTLV-1 (Seiki et al., 1983) and RSV (Schwartz et al., 1983), the motif Cys-X 2 -Cys-X 8-9 -Cys common to all NBP (Orozlan et al., 1984) is found duplicated (nucleotides 1509 and 1572 in LAV sequence). Consistent with its function the putative NBP is extremely basic (17 % Arg + Lys).
  • ORF-gag a genomic fragment (ORF-gag) thought to code for the core antigens including the p25, p18 and ⁇ 13 proteins is located between nucleotidic position 312 (starting with 5' CTA GCG GAG 3') and nucleotidic position 1835 (ending by CTCG TCA CAA 3").
  • the structure of the peptides or proteins encoded by parts of said ORF is deemed to be that corresponding to phase 2.
  • the methionine aminoacid "M" coded by the ATG at position 336-338 is the probable initiation methionine of the gag protein precursor.
  • the end of ORF-gag and accordingly of gag protein appears to be located at position 1835.
  • the invention is thus more particularly concerned with and relates to the DNA sequence, extending from nucleotide 336 up to about nucleotide 1650, deemed to encode a p55 protein which is considered a containing aminoacid sequences corresponding to those of the core proteins p18 and p25 of the LAV virus ; the DNA sequence, extending from nucleotide 732 up to about nucleotide 1300, deemed to encode the p25 protein ; - the DNA sequence, extending from about nucleotide 1371 to about nucleotide 1650, deemed to encode the p13 protein ; - the DNA sequence, extending from nucleotide 336 up to about nucleotide 611, deemed to encode the p18 protein;
  • the invention also relates to the purified polypeptides which have the aminoacid structures encoded by the abovesaid fragments, particularly the p13, p18, p25, p55 proteins or polypeptides which have the structures corresponding to those resulting from the direct translations of the DNA sequences or fragments which have been defined more specifically hereabove, which peptidic sequences flow directly from fig. 4a. More particularly the invention relates to purified polypeptides having peptidic sequences identical or equivalent to those encoded by the DNA sequences extending from the following nucleotide positions :
  • the invention further concerns polypeptide fragments encoded by corresponding DNA fragments of the gag open reading frame.
  • Those hydrophilic peptides include : aminoacids 12-32 inclusive, i.e.
  • Lys-Ala-Phe-Seraminoacids 178-188 inclusive i.e. Gly-Ala-Thr-Pro-GlnAsp-Leu-Asn-Thr-Met-Leu- aminoacids 200-220 inclusive, i.e. Met-Leu-Lys-Glu-ThrIle-Asn-Glu-Glu-Ala-Ala-Glu-Trp-Asp-Arg-Val-HisPro-Val-His-Alaaminoacids 226-234 inclusive, i.e. Gly-Gln-Met-Arg-GluPro-Arg-Gly-Seraminoacids 239-264 inclusive, i.e.
  • the invention also relates to any combination of these peptides.
  • the " pol gene " ( or ORF-pol )
  • the pol coding region is the only one in which significant homology has been f ound with other retroviral protein sequences, three domains of homology being apparent.
  • the first is a very short region of 17 aminoacids (starting at 1856).
  • Homologous regions are located within the p15 gag RSV protease (Dittmar and Moellmg 1978) and a polypeptid encoded by an open reading frame located between gag and pol of HTLV-1 (fig. 5) (Schwartz et al., 1983, Seiki et al., 1983). This first domain could thus correspond to a conserved sequence in viral proteases.
  • LAV shows 38 % aminoacid identity with RSV, 25 % with HTLV-I, 21 % with MoMuLV (Schinnick et al., 1981) while HTLV-I and RSV show 38 % identity in the same region.
  • a third homologous region is situated at the 3' end of the pol reading frame and corresponds to part of the pp32 peptide of RSV that has exonuclease activity (Misra et al., 1982). Once again, there is greater homology with the corresponding RSV sequence than with HTLV-1.
  • Figs. 4a-4c also show that the DNA fragment extending from nucleotidic position 1631 (starting with 5'TTT TTT ....3' to nucleotidic position 5162 thought to correspond to the pol gene.
  • the polypeptidic structure of the corresponding polypeptides is deemed to be that corresponding to phase 1, It stops at position 4639 (end by 5' G GAT GAG GAT 3').
  • These genes are thought to code for the virus polymerase or reverse transcriptase.
  • the envelope gene (or ORF-env) env The env open reading frame has a possible initiator methionine codon very near the beginning (8th triplet).
  • An interesting feature of env is the very high number of Trp residues at both ends of the protein.
  • nucleotidic position 5746 starting with 5' AAA GAG GAG A....3'
  • nucleotidic position 8908 ending by A ACT AAA GAA
  • Polypeptidic structures of sequences of the envelope protein correspond to those read according to the "phase 3" reading phase.
  • the start of env transcription is thought to be at the level of the ATG codon at position 5767-5769.
  • hydrophobic regions characteristic of the retroviral envelope proteins (Seiki et al., 19-83) corresponding to a signal peptide (encoded by nucleotides 5815-5850 bp), a second region (7315-7350 bp) and a transmembrane segment (7831-7890 bp).
  • the second hydrophobic region (7315-7350 bp) is preceeded by a stretch rich in Arg + Lys. It is possible that this represents a site of proteolytic cleavage, which by analogy with over retroviral proteins, would give an external envelope polypeptide and a membrane associated protein (Seiki et al., 1983, Kiyokawa et al., 1984).
  • LAV envelope protein sequence A striking feature of the LAV envelope protein sequence is that the segment encoding the transmeubrane pirotein is of unusual length (150 residues).
  • the env protein shows no homology to any sequence in protein data banks.
  • the small aminoacid motif common to the transmembrane proteins of all leukemogenic retroviruses (Cianciolo et al., 1984) is not present in lav env.
  • the invention concerns more particularly the DNA sequence extending from nucleotide 5767 up to nucleotide 7314 deemed to encode the gp 110 (envelope glycoprotein of the LAV virus which has a molecular weight of about 110,000 daltons) beginning at about nucleotide as well as the polypeptidic backbone of the glycoprotein sequence which corresponds to that having an approximate molecular weight which was initially believed to be 90,000 daltons, and which turned out to be 55,000.
  • the polypeptide resulting from the complete removal of sugar residues of gp110 can be obtained by the treatment of said gp110 with the appropriate glycosidase.
  • the invention further relates to the purified polypeptides which have the aminoacid structure (or polypeptidic backbone) of the gp110 and gp90, which correspond to the direct translation of the DNA sequences and fragraents which have been defined more specifically hereabove (figs 4d and 4e).
  • the invention further relates to polypeptides containing neutralizing epitopes.
  • the locations of neutralizing epitopes are further apparent in fig. 4d.
  • the initial protein product or polypeptide backbone of the env glycoprotein has a molecular weight in excess of 91,000. These groups are deemed to generally carry glycosylated groups.
  • the invention thus concerns with more particularity peptide sequences included in the env-proteins and excizable therefrom (or having the same aminoacid structure), having sizes not exceeding 200 aminoacids.
  • Preferred peptides of this invention (referred to hereafter as a, b, c, d, e, f) are deemed to correspond to those encoded by the nucleotide sequences which extend respectively between the following positions : a) from about 6171 to about 6276 b) " “ 6336 “ “ 6386 c) " " 6466 “ “ 6516 d) " " 6561 “ “ 6696 e) " " 6936 “ “ 7006 f) " " 7611 “ " 7746
  • hydrophilic peptides are : aminoacids 8-23 inclusive, i.e. Met-Arq-Val-Lys-Glu-LysTyr-Gln-His-Leu-Trp-Arq-Trp-Gly-Trp-Lysaminoacids 63-78 inclusive, i.e. Ser-Asp-Ala-Lys-Ala-Tyr ⁇
  • Glu-Glu-Val-Val-Ile-Arg-Ser-Ala-Asn-Phe-Thr-AspAsn-Ala-Lysaminocids 300-327 inclusive i. e. Leu-Asn-Gln-Ser-Val-GluIle-Asn-Cys-Thr-Arg-Pro-Asn-Asn-Asn-Thr-Ar ⁇ -LysSer-Ile-Arq-Ile-Gln-Arq-Gly-Pro-Gly-Argaminoacids 334-381 inclusive, i.e.
  • the invention further concerns DNA sequences which provide open reading frames defined as ORF-O, ORF-R and as
  • the viral (+) strand of the LAV genome was found to contain the statutory retroviral qenes encoding the core structural proteins (gag), reverse transcriptase (pol) and envelope protein (env), and two extra open reading frames (orf) which we call Q and F (Table 1).
  • the genetic organization of LAV, 5' LTR-gag-pol-Q-env-F-3' LTR, is unique. Whereas in all replication competent retroviruses pol and env genes overlap, in LAV they are separated by orf Q (192 amino acids) followed by four small ( ⁇ 100 triplets) orf.
  • the orf F (206 amino acids) sliqhtly overlaps the 3' end of env and is remarkable in that it is half encoded by the U3 region of the LTR.
  • Such a structure places LAV clearly apart from previously sequenced retroviruses (Fig. 2). the (-) strand is apparently non coding.
  • the additional Hindlll site of the LAV clone ⁇ J81 maps to the apparently non-codinq region between 0 and env (positions 5166-5745).
  • Starting at position 5501 is a sequence (AAGCCT) which differs by a single base (underlined) from the HindiII recognition sequence. It is to be anticipated that many of the restriction site polymorphism between different isolates will map to this region.
  • Clone ⁇ J81 has also been referred to in British application Nr. 84 23659 filed on September 15, 1984.
  • O and F
  • nucleotide positions of their respective extremities are given in Table 1 hereafter.
  • the location of orf 0 is without precedent in the structure of retroviruses.
  • Orf F is unique in that it is half encoded by the U3 element of the LTR.
  • the organization of a reconstructed LTR and viral flanking elements are shown schematically in Fiq. 6.
  • the LTR is 638 bp long and displays usual features (Chen and Barker 1984) : (I) It is bounded by an inverted repeat (5'ACTG) including the conserved TG dinucleotide (Temin)
  • Adiacent to 5" LTR is the tRNA primer binding site (PBS), complementary to tRNA (Raba et al., 1979)
  • (III) adjacent to 3' LTR is a perfect 15 bp polypurine tract.
  • the other three polypurine tracts observed between nucleotides 8200-8800 are not followed by a sequence which is complementary to that iust preceeding the PBS.
  • the limits of U5, R and U3 elements were determined as follows.
  • U5 is located between PBS and the polyadenylation site established from the sequence of the 3' end of oligo(dT)primed LAVcDNA (Alizon et al., 1984). Thus U5 is 84 bps lon ⁇ .
  • the length of R+U5 was determined by synthesizing tRNA-primed LAV cDNA.
  • R+U5 was found to be 181 ⁇ 1 bp.
  • R is 97 bps long and the capping site at its 5' end can be located.
  • U3 is 456 bp long.
  • the LAV LTR also contains characteristic requlatory elements : a polyadenylation siqnal sequence AATAAA 19 bp from the R-U5 junction and the sequence ATATAAG which is very likely the TATA box, 22 bps 5' of the cap site. There are no longer direct repeats within the LTR. Interestingly the LAV. LTR shows some similarities to that of the mouse mammary tumour virus
  • MMTV Donehower et al., 1981. They both use tRNA lys as a primer for (-) strand synthesis whereas all 3 other exogenous mammalian retroviruses known to date use tRNA pro (Chen and Barker 1984). They possess very similar polypurine tracts (that of LAV is AAAAGAAAAGGGGGG while that of MMTV is AAAAAAGAAAAAGGGGG) . It is probable that the viral (+) strand synthesis is discontinuous since the polypurine tract flanking the U3 element of the 3' LTR is found exactly duplicated in the 3' end of orf pol, at 4331-4336. In addition, MMTV and LAV are exceptionnal in that the U3element can encode an orf. In the case of MMTV, U3 contains the whole orf while in LAV, U3 contains 110 codons of the 3' half of orf F.
  • LTR long terminal repeat
  • the LTR long terminal repeats
  • the LTR can also be defined as lying between position 8560 and position 160 (end extending over position 9097/1). As a matter of fact the end of the genome is at 9097 and, because of the LTR structure of the retrovirus, links up with the beginning of the sequence
  • Table 1 sums up the locations and sizes of viral open reading frames.
  • the nucleotide coordinates refer to the first base of the first triplet (1st triplet). of the first methionine initiation codon (Met) and of the stop codon (stop).
  • the number of aminoacids and calculated molecular weights are those calculated for unmodified precursor products starting at the first methionine through to the end with the exception of pol where the size and MW refer to that of the whole orf.
  • the invention concerns more particularly all the DNA fragments which have been more specifically referred to hereabove and which correspond to open reading frames. It will be understood that the man skilled in the art will be able to obtain them all, for instance by cleaving an entire DNA corresponding to the complete genome of a LAV species, such as by cleavage by a partial or complete digestion thereof with a suitable restriction enzyme and by the subseguent recovery of the relevant fragments .
  • the different DNAs disclosed above can be resorted to also as a source of suitable fragments.
  • the technigues disclosed hereafter for the isolation of the fragments which were then included in the plasmids referred to hereabove and which were then used for the DNA seguencing can be used.
  • DNA can be transfected into mammalian cells with appropriate selection markers by a variety of techniques, calcium phosphate precipitation, polyethylene glycol, protoplast-fusion, etc..
  • DNA fraqments corresponding to genes can be cloned into expression vectors for E. coli , yeast- or mammalian cells and the resultant proteins purified.
  • the provival DNA can be "shot-gunned" (fragmented) into procarvotic expression vectors to generate fusion polypeptides. Recombinant producing antigenically competent fusion proteins can be identified by simply screening the recombinants with antibodies against LAV antigens .
  • the invention further refers more specifically to DNA recombinants, particularly modified vectors, including any of the preceding DNA sequences and adapted to transform corresponding microorganisms or cells, particularly eucaryotic.
  • cells such as yeasts, for instance saccharomyces cerevisiae, or higher eucaryotic cells, particularly cells of mammals, and to permit expression of said DNA sequences in the corresponding microorganisms or cells.
  • the invention relates to such modified DNA recombinant vectors modified by the abovesaid DNA sequences and which are capable of transforming higher eucaryotic cells particularly mammalian cells.
  • any of the abovesaid sequences are placed under the direct control of a promoter contained in said vectors and which is recognized by the polymerases of said cells, such that the first nucleotide codons expressed correspond to the first triplets of the above-defined DNA-sequences.
  • this invention also relates to the corresponding DNA fragments which can be obtained from LAV genomas or corresponding cDNAs by any appropriate method.
  • such a method comprises cleavinq said LAV genomas or cDNAs by restriction enzymes preferably at the level of restriction sites surrounding said fragments and close to the opposite extremities respectively thereof, recovering and identifying the fragments sought according to sizes, if need be checking their restriction maps or nucleotide sequences (or by reaction with monoclonal antibodies specifically directed against epitopes carried by the polypeptides encoded by said DNA fragments), and further if need be, trimming the extremities of the fragment, for instance by an exonucleolytic enzyme such as Bal31 , for the purpose of controlling the desired nucleotide-sequences of the extremities of said DNA fragments or, conversely, repairing said extremities with Klenow enzyme and possibly ligating the latter to synthetic polynucleotide fragments designed to permit the reconstitution of the nucleotide gxtremities of said fragments.
  • an exonucleolytic enzyme such as Bal31
  • Those fragments may then be inserted in any of said vectors for causing the expression of the corresponding polypeptide by the cell transformed therewith.
  • the corresponding polypeptide can then be recovered from the transformed cells, if need be after lysis thereof, and purified, by methods such as electrophoresis. Needless to say that all conventionnal methods for performing these operations can be resorted to.
  • the invention also relates more specifically to cloned probes which can be made starting from any DNA fraqment according to this invention, thus to recombinant DNAs containinq such fragments, particularly any plasmids amplifiable in procaryotic or eucaryotic cells and carrying said fragments.
  • DNA fragments as a molecular hybridization probe - either by labelling with radionucleotides or with fluorescent reagents - LAV virion RNA may be detected directly in the blood, body fluids and blood products (e.q. of the antihemophylic factors such as Factor VIII concentrates) and vaccines, i.e. hepatitis B vaccine.
  • a suitable method for achieving that detection comprises immobilizing virus onto a support, e.q. nitrocellulose filters, etc., disrupting the virion and hybridizing with labelled (radiolabelled or "cold" fluorescent- or enzyme-labelled) probes.
  • labelled radiolabelled or "cold" fluorescent- or enzyme-labelled
  • Probes according to the invention can also be used for rapid screening of genomic DNA derived from the tissue of patients with LAV related symptoms, to see if the proviral DNA or RNA is present in host tissue and other tissues.
  • a method which can be used for such screening comprises the following steps : extraction of DNA from tissue, restriction enzyme cleavage of said DNA, electrophoresis of the fragments and Southern blotting of genomic DNA from tissues, subseguent hybridization with labelled cloned LAV provival DNA. Hybridization in situ can also be used.
  • Lymphatic fluids and tissues and other non-lymphatic tissues of humans, primates and other mammalian species can also be screened to see if other evolutionnary related retrovirus exist.
  • the methods referred to hereabove can be used, although hybridization and washinqs would be done under non stringent conditions.
  • the DNAs or DNA fraqments according to the invention can be used also for achieving the expression of LAV viral antiqens for diagnostic purposes.
  • the invention relates generally to the polypeptides themselves, whether synthetized chemically isolated from viral preparation or expressed by the different DNAs of the inventions, particularly by the ORFs or fragments thereof, in appropriate hosts, particularly procaryotic or eucaryotic hosts, after transformation thereof with a suitable vector previously modified by the corresonding DNAs.
  • the invention also relates to any of the polypeptide fragments (or molecules, particularly glycoproteins having the same polypeptidic backbone as the polypeptides mentioned hereabove) bearing an epitope characteristic of a LAV protein or glycoprotein, which polypeptide or molecule then has N-terminal and C-terminal extremities respectively either free or, independently from each other, covalently bond to aminoacids other than those which are normally associated with them in the larger polypeptides or glycoproteins of the LAV virus, which last mentioned aminoacids are then free or belong to another polypeptidic sequence.
  • the invention relates to hybrid polypeptides containing any of the epitope-bearing-polypeptides which have been defined more specifically hereabove, recombined with other polypeptides fragments normally foreign to the LAV proteins, having sizes sufficient to provide for an increased immunogenicity of the epitope-bearing-polypeptide yet, said foreign polypeptide fragments either being immunogenically inert or not interfering with the immunogenic properties of the epitope-bearing-polypeptide.
  • hybrid polypeptides which may contain up to 150, even 250 aminoacids usually consist of the expression products of a vector which contained ab initio a nucleic acid seguence expressible under the control of a suitable promoter or replicon in a suitable host, which nucleic acid seguence had however beforehand been modified by insertion therein of a DNA seguence encoding said epitope-bearing-polypeptide.
  • Said epitope-bearing-polypeptides are also accessible by chemical synthesis, according to technics well known in the chemistry of proteins.
  • This method of synthesis consists of successively condensing either the successive aminoacids in twos, in the appropriate order or successive peptide fraqments previously available or formed and containing already several aminoacyl residues in the appropriate order respectively. Except for the carboxyl and aminoqroups which will be enqaqed in the formation of the peptide bonds, care must be taken to protect beforehand all other reactive groups borne by these aminoacyl groups or fragments. However, prior to the formation of the peptide bonds, the carboxvl groups are advantageously activated, according to methods well known in the synthesis of peptides.
  • aminoacid by aminoacid the synthesis starts preferably by the condensation of the C-terminal aminoacid with the aminoacid which corresponds to the neighboring aminoacyl group in the desired seguence and so on, step by step, up to the N-terminal aminoacid.
  • Another preferred technigue can be relied upon is that described by R.D. Merrifield in "solid phase peptide synthesis” (J. Am. Chem. Soc., 45, 21492154).
  • the first C-terminal aminoacid of the chain is fixed to a suitable porous polymeric resin, by means of its carboxylie group, the amino group of said aminoacid then being protected , for example by a t-butyloxycarbonyl qroup.
  • the protective group of the amine group is removed by washing the resin with an acid, i.e. trifluoroacetic acid, when the protective group of the amine group is a t-butyloxycarbonyl group.
  • the carboxylic group of the second aminoacid which is to provide the second aminoacyl group of the desired peptidic sequence, is coupled to the deprotected amine group of the C-terminal aminoacid fixed to the resin.
  • the carboxyl group of this second aminoacid has been activated, for example by dicyclohexylcarbodiimide, while its amine group has been protected, for example by a t-butyloxvcarbonyl group.
  • the first part of the desired peptide chain, which comprising the first two aminoacids, is thus obtained.
  • the amine group is then deprotected, and one can further proceed with the fixing of the next aminoacyl group and so forth until the whole peptide sought is obtained.
  • the protective groups of the different side groups, if any, of the peptide chain so formed can then be removed.
  • the peptide sought can then be detached from the resin, for example, by means of hydrofluoric acid, and finally recovered in pure form from the acid solution according to conventional procedures.
  • peptide sequences of smgllest size and bearing an epitope or imunogenic determinant may be required, in order to increase their in vivo immunogenic character, to couple or "coniugate" them covalently to a physiologically acceptable and non toxic carrier molecule.
  • carrier molecules or macromolecular supports which can be used for making the coniugates according to the invention; will be mentioned natural proteins, such as tetanic toxoid, ovalbumin, serum-albumins, hemocvanins, etc..
  • synthetic macromolecular carriers for example polysines or poly (D-L-alanine)-poly(L-lysine)s, can be used too.
  • macromolecular carriers which can be used, which generally have molecular weights higher than 20,000, are known from the literature.
  • the coniugates can be synthesized by known processes, such as described by Frantz and Robertson in "Infect. and Immunity”. 33, 193-198 (1981), or by P.E. Kauffman in Applied and Environmental Microbiology, October 1981, Vol. 42, n . 4, 611-614.
  • the following coupling agents can be used : glutaric aldehyde, ethyl chloroformate, water-soluble carbodiimides (N-ethyl-N' (3-dimethylaminopropyl) carbodiimide, HCl), diisocyanates, bis-diazobenzidine, di- and trichloro-s-triazines, cyanogen bromides, benzaguinone, as well as coupling agents mentioned in "Scand. J. Immunol., 1978, vol. 8, P. 7-23 (Avrameas, Ternynck, Guesdon).
  • Any coupling process can be used for bonding one or several reactive groups of the peptide, on the one hand, and one or several reactive grouos of the carrier, on the other hand.
  • coupling is advantageously achieved between carboxyl and amine groups carried by the peptide and the carrier or vice-versa in the presence of a coupling agent of the type used in protein synthesis, i.e. 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide, N-hydroxybenzotriazole, etc.
  • Coupling between amine groups respectively borne by the peptide and the carrier can also be made with glutaraldehyde, for instance, according to the method described by BOQUET, P. et al. (1982) Molec. Immunol., 19, 1441-1549, when the carrier is hemocyanin.
  • the immunogenicity of epitope-bearingpeptides can also be reinforced, by oligomerisation thereof, for example in the presence of glutaraldehyde or any other suitable coupling agent.
  • the invention relates to the water soluble immunogenic oliqomers thus obtained, comprising particularly from 2 to 10 monomer units.
  • glycoproteins, proteins and polypeptides are useful in processes for the detection of the presence of anti-LAV antibodies in biological media, particularly biological fluids such as sera from man or animal, particularly with a view of possibly diagnosing LAS or AIDS.
  • the invention relates to an in vitro process of diagnosis making use of an envelope glycoprotein (or of a polypeptide bearing an epitope of this glycoprotein) for the detection of anti-LAV antibodies in the serums of persons who carry them.
  • Other polypeptides - particular those carrying an epitope of a core protein - can be used too.
  • a preferred embodiment of the process of the invention comprises : - depositing a predetermined amount of one or several of said antigens in the CUPS of a titration miroplate ; introducing of increasing dilutions of the biological fluid, i.e. serum to be diagnosed into these CUPS : - incubating the microplate : - washing carefully the microplate with an appropriate buffer : adding into the cups specific labelled antibodies directed against blood immunoglobulins and detecting the antigen-antibody-complex formed, which is then indicative of the presence of LAV antibodies in the biological fluid.
  • the labelling of the antiimmunoglobulin antibodies is achieved by an enzyme selected from among those which are capable of hydrolysing a substrate, which substrate undergoes a modification of its radiation-absorption, at least within a predetermined band of wavelenghts.
  • the detection of the substrate preferably comparatively with respect to a control, then provides a measurement of the potential risks or of the effective presence of the disease.
  • Titrations may be determinations by immunofluorescence or direct or indirect immunoenzymatic determinations. Quantitative titrations of antibodies on the serums studied can be made.
  • kits themselves for the in vitro detection of antibodies a ⁇ ainst the LAV virus, which kits comprise any of the polypeptides identified herein, and all the biolo ⁇ ical and chemical reagents, as well as equipment, necessary for peforming diagnostic assays.
  • kits comprise all reagents required for carrving out ELISA assays.
  • preferred kits will include, in addition to any of said polypeptides, suitable buffers and anti-human immunoqlobulins, which anti-human immunoglobulins are labelled either by an immunofluorescent molecule or by an enzyme.
  • kits then also comprise a substrate hydrolysable by the enzyme and providing a siqnal, particularly modified absorption of a radiation, at least in a determined wavelength, which signal is then indicative of the presence of antibody in the biological fluid to be assayed with said kit.
  • the invention also relates to vaccine compositions whose active principle is to be constituted by any of the antigens, i.e. the hereabove disclosed polypeptides whole antigens, particularly the purified gp110 or immunogenic fragments thereof, fusion polypeptides or oligopeptides in association with a suitable pharmaceutical or physiologically acceptable carrier.
  • a first type of preferred active principle is the gp110 immunogeh.
  • peptides containing less than 250 aminoacid units, preferably less than 150, as deducible for the complete genomas of LAV, and even more preferably those peptides which contain one or more groups selected from Asn-X-Ser and Asn-X-Ser as defined above.
  • Preferred peptides for use in the production of vaccinating principles are peptides (a) to (f) as defined above.
  • suitable dosages of the vaccine compositions are those which are effective to elicit antibodies in vivo, in the host, particularly a human host. Suitable doses ranqe from 10 to 500 micrograms of polypeptide. protein or glycoprotein per kq, for instance 50 to 100 microqrams per kg.
  • the different peptides according to this invention can also be used themselves for the production of antibodies, preferably monoclonal antibodies specific of the different peptides respectively.
  • monoclonal antibodies specific of the different peptides respectively.
  • hybridomas secreting said monoclonal antibodies conventional production and screening methods are used.
  • monoclonal antibodies, which themselves are part of the invention then provide very useful tools for the identification and even determination of relative proportions of the different polypeptides or proteins in biological samples, particularly human samples containing LAV or related viruses.
  • the invention further relates to the hosts (procarvotic or eucaryotic cells) which are transformed by the above mentioned recombinants and which are capable of expressing said DNA fraqments.
  • the invention also concerns vectors for the transformation of eucaryotic cells of human origin, particularly lymphocytes, the polymerases of which are capable of recognizing the LTRs of LAV.
  • vectors are characterized by the presence of a LAV LTR therein, said LTR being then active as a promoter enabling the efficient transcription and translation in a suitable host of a DNA insert coding for a determined protein placed under its controls.
  • the invention extends to all variants of genomes and corresponding DNA fragments (ORFs) having substantially equivalent properties, all of said genomes belonging to retroviruses which can be considered as equivalents of LAV.
  • ORFs DNA fragments
  • the claims which follow are also intended to cover all equivalents of the products (glycoproteins, polypeptides, DNAs, etc.), whereby an equivalent is a product, i.e. a polypeptide which may distinguish from a determined one defined in any of said claims, say through one or several aminoacids, while still having substantially the same immunological or immunogenic properties.
  • a similar rule of eguivalency shall apply to the DNAs , it being understood that the rule of equivalency will then be tied to the rule of equivalency pertaining to the polypeptides which they encode.
  • LAV lymphadenopathy associated virus
  • Bovine leukemia virus Unique structural features of its long terminal repeats and its evolutionary relationship to human T-ceil leukemia virus. Proc. Natl. Acad. Sci. USA 81, 4741-4745.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • AIDS & HIV (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)

Abstract

Produits purifiés d'expression de séquences d'ADN dérivées du génome du virus LAV. On décrit particulièrement une glycoprotéine possédant un poids moléculaire d'environ 110 000 ou un antigène de poids moléculaire inférieur dérivé de ladite glycoprotéine, ce produit purifié pouvant être reconnu par des sérums d'origine humaine et contenant des anticorps contre le virus LAV. L'invention se rapporte également à d'autres polypeptides purifiés dérivés soit de ladite glycoprotéine soit de protéines de noyau du virus LAV. La glycoprotéine peut être utilisée pour la production de compositions immunogènes pouvant neutraliser le virus LAV. La glycoprotéine ou les polypeptides ci-décrits peuvent être utilisés comme antigènes utiles dans le diagnostic d'anticorps du LAV dans les sérum prélevés chez les patients.
PCT/EP1985/000548 1984-10-18 1985-10-18 Antigenes d'enveloppe du virus des lymphadenopathies et leurs applications WO1986002383A1 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
KR1019860700374A KR930000189B1 (ko) 1984-10-18 1985-10-18 임파선증과 후천성 면역 결핍증 바이러스의 항원을 제조하는 방법 및 이 항원에 대한 항체의 생산 방법
AT85905513T ATE64601T1 (de) 1984-10-18 1985-10-18 Lymphadenopathie-assoziierte huellenantigene und deren verwendungen.
DE8585905513T DE3583293D1 (de) 1984-10-18 1985-10-18 Lymphadenopathie-assoziierte huellenantigene und deren verwendungen.
EP85905513A EP0201540B2 (fr) 1984-10-18 1985-10-18 Antigenes d'enveloppe du virus des lymphadenopathies et leurs applications
DK198602849A DK174910B1 (da) 1984-10-18 1986-06-18 Antigen, fremgangsmåde til fremstilling af antigenet, fremgangsmåde til diagnosticering samt immunogene præparater

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
FR8416013A FR2571968B1 (fr) 1984-10-18 1984-10-18 Virus purifie des lymphadenopathies et du syndrome d'immuno-depression acquise et antigenes d'enveloppe de ce virus, procede d'obtention de ce virus et de ces antigenes d'enveloppe de ce virus, applications de ce virus ou de ces antigenes a la preparation de compositions immunogenes ou pour le diagnostic des susdites affections.
FR84/16013 1984-10-18
GB8429099 1984-11-16
GB848429099A GB8429099D0 (en) 1984-11-16 1984-11-16 Closed dna sequences
GB858501473A GB8501473D0 (en) 1985-01-21 1985-01-21 Cloned dna sequences
GB8501473 1985-01-21

Publications (1)

Publication Number Publication Date
WO1986002383A1 true WO1986002383A1 (fr) 1986-04-24

Family

ID=27251244

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1985/000548 WO1986002383A1 (fr) 1984-10-18 1985-10-18 Antigenes d'enveloppe du virus des lymphadenopathies et leurs applications

Country Status (15)

Country Link
EP (5) EP0462627B2 (fr)
JP (4) JP2752329B2 (fr)
KR (1) KR930000189B1 (fr)
AT (6) ATE373010T1 (fr)
AU (1) AU603543B2 (fr)
CA (1) CA1341620C (fr)
DE (7) DE3583293D1 (fr)
DK (2) DK174910B1 (fr)
ES (3) ES8705522A1 (fr)
GR (1) GR852522B (fr)
HK (2) HK1050215B (fr)
IE (1) IE64006B1 (fr)
NZ (1) NZ230372A (fr)
PT (1) PT81338B (fr)
WO (1) WO1986002383A1 (fr)

Cited By (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0201588A1 (fr) * 1984-11-09 1986-11-20 Harvard College Analyse de detection d'une infection par un virus lymphotrophique de cellules t humaines.
FR2587720A2 (fr) * 1985-09-25 1987-03-27 Oncogen Vaccin contre le syndrome immunodeficitaire acquis et intermediaires immunogeniques pour la preparation de ce vaccin et pour des dosages immunologiques de depistage de ce syndrome
EP0219106A2 (fr) * 1985-10-17 1987-04-22 F. Hoffmann-La Roche Ag Polypeptides induisant des anticorps contre le virus du SIDA
FR2593519A1 (fr) * 1985-09-25 1987-07-31 Oncogen Vaccin contre le syndrome immunodeficitaire acquis et intermediaires pour la preparation de ce vaccin
EP0231914A2 (fr) * 1986-02-03 1987-08-12 F. Hoffmann-La Roche Ag Peptides d'enveloppe de HTLV-III
EP0233045A2 (fr) * 1986-02-03 1987-08-19 Cambridge Biotech Corporation Peptides pour le diagnostic des anticorps HTLV-III, ainsi que leur préparation et leur utilisation
EP0245362A1 (fr) * 1985-10-24 1987-11-19 Southwest Found Biomed Res Peptides synthetiques et leur utilisation pour le diagnostic et la vaccination contre le sida et son complexe associe.
FR2601457A1 (fr) * 1986-07-08 1988-01-15 Bio Rad Laboratories Procede de differenciation des etats pathologiques dans des essais utilisant des anticorps anti-sida
EP0255190A2 (fr) * 1986-08-01 1988-02-03 Repligen Corporation Polypeptides recombinants et leurs applications, ainsi qu'essai pour le virus du SIDA
FR2603107A1 (fr) * 1986-08-20 1988-02-26 Genetic Systems Corp Compositions, vaccin et anticorps monoclonaux utiles pour le traitement des affections par le virus hiv et procedes de production de ces anticorps et de diagnostic de la presence de ce virus
EP0260714A2 (fr) * 1986-09-19 1988-03-23 Oncogen Limited Partnership Utilisation de lymphocytes T actives dans la préparation d'un médicament pour le traitement du SIDA
EP0267802A2 (fr) * 1986-11-14 1988-05-18 Genetic Systems Corporation Antigène synthétique pour la détection de maladie de SIDA et maladies s'y rapportant
EP0269712A1 (fr) * 1986-06-12 1988-06-08 Biogen, Inc. Peptides impliques dans la pathogenese d'une infection du type hiv
WO1988005440A1 (fr) * 1987-01-16 1988-07-28 Institut Pasteur Peptides ayant des proprietes immunologiques 2-hiv-2
FR2610632A1 (fr) * 1987-02-11 1988-08-12 Pasteur Institut Peptides caracteristiques des retrovirus d'immunodeficience humaine (virus hiv) leurs applications au diagnostic des infections dues a certains de ces virus et, le cas echeant, a la vaccination contre le sida
EP0278148A2 (fr) * 1987-02-10 1988-08-17 United Biomedical, Inc. Composition peptidique et procédé pour la détection d'anticorps contre HTLV-III
EP0284587A2 (fr) * 1987-03-27 1988-09-28 Syntello Ab Antigènes peptides synthétiques pour la détection d'infections de HIV-1
FR2614025A1 (fr) * 1987-04-15 1988-10-21 Pasteur Institut Peptides susceptibles d'etre reconnus par des anticorps induits contre des retrovirus d'immunodeficience humaine (virus hiv) leurs applications au diagnostic des infections dues a certains de ces virus et, le cas echeant, a la vaccination contre le sida
WO1988008429A1 (fr) * 1987-04-24 1988-11-03 Biogen N.V. Procedes et compositions immunotherapeutiques
WO1988009181A2 (fr) * 1987-05-29 1988-12-01 Tanox Biosystems, Inc. Anticorps monoclonaux neutralisant le hiv-1
WO1988009339A1 (fr) * 1987-05-29 1988-12-01 Labsystems Oy Polypeptide hiv, sa preparation et utilisation pour la detection d'anticorps hiv
WO1988010267A1 (fr) * 1987-06-24 1988-12-29 Proteus Biotechnology Limited Peptides synthetiques apparentes a des proteines hiv-env
EP0311219A1 (fr) * 1987-10-09 1989-04-12 Stichting Centraal Diergeneeskundig Instituut Oligopeptide et leur application pour le diagnostic et la vaccination relatifs au SIDA et â l'ARC
EP0317804A2 (fr) * 1987-11-24 1989-05-31 Abbott Laboratories Peptides de VIH et méthodes de détection de VIH
US4839288A (en) * 1986-01-22 1989-06-13 Institut Pasteur Retrovirus capable of causing AIDS, antigens obtained from this retrovirus and corresponding antibodies and their application for diagnostic purposes
WO1989006240A1 (fr) * 1987-12-30 1989-07-13 Jonas Blomberg PEPTIDE CORRESPONDANT AU VIH-env 583-599, ET SES ANALOGUES, AINSI QUE LES APPLICATIONS DES PEPTIDES
EP0328403A2 (fr) * 1988-02-12 1989-08-16 United Biomedical Inc. Peptides synthétiques relatifs à la protéine HIV-GP120-env. et leur application
EP0279688A3 (fr) * 1987-02-20 1989-09-13 Genentech, Inc. Méthodes et compositions pour l'utilisation de polypeptides env et anticorps anti-env de HIV
EP0239425B1 (fr) * 1986-01-22 1989-11-02 Institut Pasteur Rétrovirus du type HIV-2 susceptible de provoquer le SIDA, et ses constituants antigéniques et nucléiques
EP0339504A2 (fr) * 1988-04-26 1989-11-02 The Du Pont Merck Pharmaceutical Company Virus d'immunodéficience humaine (HIV) peptide env-codé capable de provoquer les anticorps inhibiteurs du HIV dans les mammifères
FR2632310A1 (fr) * 1988-06-06 1989-12-08 Pasteur Institut Peptides ayant des proprietes protectrices d'un virus pathogene du type hiv dans des cellules sensibles
EP0345375A1 (fr) * 1988-06-09 1989-12-13 N.V. Innogenetics S.A. Rétrovirus HIV-3 et son utilisation
US4943627A (en) * 1986-06-12 1990-07-24 Biogen, Inc. Peptides involved in the pathogenesis of HIV infection
WO1990013564A1 (fr) * 1989-05-03 1990-11-15 Connaught Laboratories Limited Peptides synthetiques pour vaccin contre l'hiv-1
EP0400076A1 (fr) * 1988-01-26 1990-12-05 Us Health Antigene synthetique suscitant une reaction anti-vih.
FR2647810A1 (fr) * 1989-06-02 1990-12-07 Pasteur Institut Amorces oligonucleotidiques pour l'amplification du genome des retrovirus du type hiv-2 et siv, et leurs applications au diagnostic in vitro des infections dues a ces virus
EP0418347A1 (fr) * 1989-02-28 1991-03-27 New York University Anticorps monoclonaux humains contre le virus d'immunodeficience humaine
US5017688A (en) * 1986-06-12 1991-05-21 Biogen, Inc. Peptides involved in the pathogenesis of HIV infection
WO1991009869A1 (fr) * 1990-01-05 1991-07-11 Medical Research Council Fragments de la proteine du noyau de vih-1
WO1991013360A1 (fr) * 1990-02-20 1991-09-05 Replico Medical Aktiebolag NOUVEAUX PEPTIDES D'HIV p24, ANTIGENES DIAGNOSTIQUES ET METHODE D'IMMUNO-ANALYSE DISCRIMINANTE
WO1991009872A3 (fr) * 1989-12-13 1992-04-02 Univax Biolog Inc Polypeptides selectivement reactifs avec des anticorps contre le virus d'immunodeficience humaine et vaccins comprenant les polypeptides
WO1992006199A2 (fr) * 1990-09-27 1992-04-16 Institut Pasteur Peptides inducteurs d'anticorps inhibant des retrovirus du type hiv et anticorps diriges contre ces peptides
WO1992005800A1 (fr) * 1990-09-27 1992-04-16 Syntello Vaccin Development Kb Peptides destines a etre utilises dans la vaccination et dans l'induction d'anticorps neutralisants pour lutter contre le virus d'immunodeficience humaine
EP0494317A1 (fr) 1990-06-15 1992-07-15 Innogenetics N.V. Le rétrovirus SIV cpz-ant et ses applications
EP0495465A2 (fr) * 1991-01-15 1992-07-22 Coulston International Corporation Essai immuno-enzymatique pour détecter des anticorps virales
US5156949A (en) * 1984-10-31 1992-10-20 Chiron Corporation Immunoassays for antibody to human immunodeficiency virus using recombinant antigens
US5166050A (en) * 1986-08-20 1992-11-24 Bristol-Myers Squibb Company Monoclonal antibodies and peptides useful in treating and diagnosing HIV infections
WO1992021377A1 (fr) * 1991-06-03 1992-12-10 Syntello Inc. Peptides a utiliser pour induire l'activation de lymphocytes t contre le vih-1
FR2677364A1 (fr) * 1991-06-05 1992-12-11 Pasteur Institut Sequences peptidiques de la glycoproteine externe d'enveloppe du retrovirus hiv-1.
US5185147A (en) * 1988-08-19 1993-02-09 Cellular Products, Inc. Short polypeptide sequences useful in the production and detection of antibodies against human immunodeficiency virus
EP0552850A1 (fr) 1984-10-10 1993-07-28 Centocor, Inc. Clonage et expression d'ADN de HTLV-III
US5328835A (en) * 1985-04-08 1994-07-12 Bristol-Myers Squibb Company Expression of immunologically reactive HIV envelope proteins
US5346989A (en) * 1990-08-22 1994-09-13 Syntello Vaccine Development Kb Peptides for use in induction of T cell activation against HIV-1
US5562905A (en) * 1988-04-26 1996-10-08 E. I. Du Pont De Nemours And Company Human immunodeficiency virus (hiv) env-coded peptide capable of eliciting hiv-inhibiting antibodies in mammals
US5610035A (en) * 1983-12-05 1997-03-11 Institut Pasteur Centre National De La Recherche Scientific Methods for the preparation of hybridomas producing lymphadenopathy-associated virus (LAV) GP110-specific monoclonal antibodies and methods for the purification of GP110 employing said monoclonal antibodies
US5683701A (en) * 1988-06-10 1997-11-04 United Biomedical, Inc. Peptide fragments of HIV
EP0806484A2 (fr) * 1989-06-02 1997-11-12 Institut Pasteur Séquences nucléotidiques issues du genome des rétrovirus du type hiv-1, hiv-2 et siv, et leurs applications notamment pour l'amplification des genomes de ces rétrovirus et pour le diagnostic in vitro des infections dues à ces virus
US5731189A (en) * 1989-02-28 1998-03-24 New York University Human monoclonal antibodies to human immunodeficiency virus
US5763160A (en) * 1988-02-12 1998-06-09 United Biomedical, Inc. Synthetic peptides and process of using same for the detection of antibodies to human immunodeficiency virus (HIV) gp120 envelope protein, diagnosis of AIDS and pre-AIDS conditions and as vaccines
FR2756843A1 (fr) * 1996-12-09 1998-06-12 Inst Nat Sante Rech Med Souches de vih-1 non-m non-o, fragments et applications
US5773210A (en) * 1985-04-19 1998-06-30 The United States Of America As Represented By The Department Of Health And Human Services Acquired immune deficiency syndrome (AIDS) viral envelope protein and method of testing for AIDS
US5820865A (en) * 1988-01-26 1998-10-13 The United States Of America As Represented By The Department Of Health And Human Services Method to induce cytotoxic T Lymphocytes specific for a broad array of HIV-1 isolates using hybrid synthetic peptides
US5830634A (en) * 1994-02-23 1998-11-03 Dade Behring Marburg Gmbh Peptides derived from a retrovirus of the HIV group and their use
US5834599A (en) * 1987-05-29 1998-11-10 Tanox Biosystems, Inc. Immunoconjugates which neutralize HIV-1 infection
US5840313A (en) * 1990-09-27 1998-11-24 Syntello Vaccine Development Kb Peptides for use in vaccination and induction of neutralizing antibodies against human immunodeficiency virus
US5871746A (en) * 1990-12-18 1999-02-16 Institut National De La Sainte Et De La Recherche Medicale (Inserm) Cytotoxic T lymphocyte-inducing lipopeptides and use as vaccines
US5976541A (en) * 1988-01-26 1999-11-02 The United States Of America As Represented By The Department Of Health And Human Services Potent peptide for stimulation of cytotoxic T lymphocytes specific for the HIV-1 envelope
US5981278A (en) * 1987-05-29 1999-11-09 Tanox, Inc. Chimeric monoclonal antibodies which neutralize HIV-1 infection and their applications in therapy and prevention for AIDS
US6013432A (en) * 1984-10-31 2000-01-11 Chiron Corporation Immunoassay of HIV antibodies using recombinant or synthetic selected pol sequence
US6077935A (en) * 1985-04-19 2000-06-20 The United States Of America As Represented By The Department Of Health And Human Services Acquired immune deficiency syndrome (AIDS) viral envelope protein and method of testing for AIDS
US6130314A (en) * 1986-03-26 2000-10-10 Genetic Systems Corporation Synthetic antigen for the detection of AIDS-related disease
US6165710A (en) * 1989-10-23 2000-12-26 Robinson; James E. Method for immobilizing viral glycoproteins for use in solid-phase immunoassays
US6214539B1 (en) 1985-04-29 2001-04-10 Bio-Rad Laboratories Synthetic antigen the detection of aids-related disease
US6514691B1 (en) 1986-01-22 2003-02-04 Institut Pasteur Peptides of human immunodeficiency virus type 2 (HIV-2), antibodies against peptides of HIV-2, and methods and kits for detecting HIV-2
US6534285B1 (en) 1984-12-24 2003-03-18 Genentech, Inc. Molecularly cloned acquired immunodeficiency syndrome polypeptides and their methods of use
US6657050B1 (en) 1987-05-29 2003-12-02 Tanox, Inc. Chimeric viral-neutralizing immunoglobulins
EP1307130A4 (fr) * 2000-02-04 2005-01-12 Beth Israel Hospital Vaccin contre le virus de l'immunodeficience humaine
US7022814B1 (en) 1992-01-21 2006-04-04 Institut Pasteur And Institut National De La Sante Et De La Recherche Medicale Nucleotide sequences derived from the genome of retroviruses of the HIV-1, HIV-2 and SIV type, and their uses in particular for the amplification of the genomes of these retroviruses and for the in vitro diagnosis of the diseases due to these viruses
US7122190B2 (en) 1993-06-07 2006-10-17 Duke University Fusion proteins comprising DP-178 and other viral fusion inhibitor peptides useful for treating aids
US7285271B1 (en) 1984-10-31 2007-10-23 Novartis Vaccines And Diagnostics, Inc. Antigenic composition comprising an HIV gag or env polypeptide
US7393949B1 (en) 1987-12-24 2008-07-01 Novartis Vaccines And Diagnostics, Inc. Human immunodeficiency virus (HIV) nucleotide sequences

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8423659D0 (en) * 1984-09-19 1984-10-24 Pasteur Institut Cloned dna sequences
AU592258B2 (en) * 1986-12-30 1990-01-04 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Synthetic peptides which induce cellular immunity to the aids virus and aids viral proteins
FR2677654B1 (fr) * 1991-06-17 1995-11-17 Pasteur Merieux Serums Vacc Composes a effet immunogene anti-cytokine, a effet immunogene anticytostatique ou a effet vaccinal anti-infection a hiv.
EP0868196A4 (fr) * 1995-10-20 2004-11-24 Univ Duke Vaccin de synthese pour la protection contre l'infection par le virus de l'immunodeficience humaine
FR2767337B1 (fr) 1997-08-14 2002-07-05 Pasteur Institut Sequences nucleiques de polypeptides exportes de mycobacteri es, vecteurs les comprenant et applications au diagnostic et a la prevention de la tuberculose
US20030044771A1 (en) * 2001-08-30 2003-03-06 Anderson Norman G. Method for discovering new infectious particles
ATE469963T1 (de) 2002-04-05 2010-06-15 Pasteur Institut Identifizierung der virulenz-assoziierten regionen rd1 und rd5, die die entwicklung von verbesserten impfstoffen mit m. bovis bcg und m. microti ermöglicht
ES2366185T3 (es) 2003-04-11 2011-10-18 Institut Pasteur Vacunas de péptidos sintéticas para vih: el epítopo de cbd como un inmunógeno eficaz para provocar anticuerpos ampliamente neutralizantes contra el vih.

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0113078A2 (fr) * 1982-12-07 1984-07-11 Juridical Foundation Japanese Foundation For Cancer Research ADN complémentaire à l'ARN du virus de la leucémie humaine
EP0115459A2 (fr) * 1983-01-26 1984-08-08 University Of Medicine And Dentistry Of New Jersey Prédiction hématologique de la Sepsis et des autres étapes de maladie
WO1984004327A1 (fr) * 1983-04-27 1984-11-08 Harvard College Procede et produits de detection du virus de la leucemie de cellules t humaines
US4520113A (en) * 1984-04-23 1985-05-28 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Serological detection of antibodies to HTLV-III in sera of patients with AIDS and pre-AIDS conditions

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8423659D0 (en) * 1984-09-19 1984-10-24 Pasteur Institut Cloned dna sequences
JPS60226658A (ja) * 1984-04-25 1985-11-11 Matsushita Electric Works Ltd 加熱器
JPS60246102A (ja) * 1984-05-21 1985-12-05 Matsushita Electric Ind Co Ltd 分布結合回路
IL76082A (en) 1984-08-22 1991-07-18 Us Health Molecular clones of the genome of htlv-iii and a process for the preparation thereof
US9328391B1 (en) 1984-08-22 2016-05-03 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Cloning and expression of HIV-1 DNA
JPS6226300A (ja) * 1984-10-10 1987-02-04 セントコ−・インコ−ポレ−テツド Ｈｔｌｖ−３ｄｎａのクロ−ニングおよび発現
CA1341423C (fr) * 1984-10-31 2003-03-04 Paul A. Luciw Proteines recombinantes de virus associes au syndrome d'adenopathie et/ou au syndrome d'immuno-deficience acquise
DE3588134T2 (de) 1984-12-24 1997-03-20 Genentech Inc Fusionen von AIDS-verwandten Polypeptiden

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0113078A2 (fr) * 1982-12-07 1984-07-11 Juridical Foundation Japanese Foundation For Cancer Research ADN complémentaire à l'ARN du virus de la leucémie humaine
EP0115459A2 (fr) * 1983-01-26 1984-08-08 University Of Medicine And Dentistry Of New Jersey Prédiction hématologique de la Sepsis et des autres étapes de maladie
WO1984004327A1 (fr) * 1983-04-27 1984-11-08 Harvard College Procede et produits de detection du virus de la leucemie de cellules t humaines
US4520113A (en) * 1984-04-23 1985-05-28 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Serological detection of antibodies to HTLV-III in sera of patients with AIDS and pre-AIDS conditions

Non-Patent Citations (16)

* Cited by examiner, † Cited by third party
Title
"CHARACTERIZATION OF ENVELOPE AND CORE STRUCTURAL GENE PRODUCTS OF HTLV-III WITH SERA FROM AIDS PATIENTS", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE, US, vol. 228, 3 May 1985 (1985-05-03), US, pages 593 - 595, XP008052488, ISSN: 0036-8075, DOI: 10.1126/science.2984774 *
"MAJOR GLYCOPROTEIN ANTIGENS THAT INDUCE ANTIBODIES IN AIDS PATIENTS ARE ENCODED BY HTLV-III", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE, US, vol. 228, 31 May 1985 (1985-05-31), US, pages 1091 - 1094, XP008052487, ISSN: 0036-8075, DOI: 10.1126/science.2986290 *
"VIRUS ENVELOPE PROTEIN OF HTLV-III REPRESENTS MAJOR TARGET ANTIGEN FOR ANTIBODIES IN AIDS PATIENTS.", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE, US, vol. 228., 1 January 1985 (1985-01-01), US, pages 1094 - 1096., XP000916624, ISSN: 0036-8075, DOI: 10.1126/science.2986291 *
ALIZON M ET AL: "Molecular cloning of lymphadenopathy-associated virus", NATURE, NATURE PUBLISHING GROUP, UNITED KINGDOM, vol. 312, 1 January 1984 (1984-01-01), United Kingdom, pages 757 - 760, XP002208977, ISSN: 0028-0836, DOI: 10.1038/312757a0 *
CHANG N T, ET AL.: "AN HTLV-III PEPTIDE PRODUCED BY RECOMBINANT DNA IS IMMUNOREACTIVE WITH SERA FROM PATIENTS WITH AIDS", NATURE, NATURE PUBLISHING GROUP, UNITED KINGDOM, vol. 315, 9 May 1985 (1985-05-09), United Kingdom, pages 151 - 154, XP001018962, ISSN: 0028-0836, DOI: 10.1038/315151a0 *
CHANG T. W., ET AL.: "DETECTION OF ANTIBODIES TO HUMAN T-CELL LYMPHOTROPIC VIRUS-III (HTLV-III) WITH ANS IMMUNOASSAY EMPLOYING A RECOMBINANT ESCHERICHIAEMPLOYING A RECOMBINANT ESCHERICHIA COLI-DERIVED VIRAL ANTIGENIC PEPTIDE.", BIOTECHNOLOGY. THE INTERNATIONAL MONTHLY FOR INDUSTRIAL BIOLOGY, NATURE PUBLISHING GROUP, US, vol. 03., no. 10., 1 October 1985 (1985-10-01), US, pages 905 - 909., XP000605233, ISSN: 0733-222X, DOI: 10.1038/nbt1085-905 *
Chemical Abstracts Service (C A S); 1 January 1985 (1985-01-01), CROWL R, ET AL.: "HTLV-III ENV GENE PRODUCTS SYNTHESIZED IN E. COLI ARE RECOGNIZED BY ANTIBODIES PRESENT IN THE SERA OF AIDS PATIENTS", XP008052572 *
Chemical Abstracts Service (C A S); 1 January 1985 (1985-01-01), MONTAGNIER L, ET AL.: "IDENTIFICATION AND ANTIGENICITY OF THE MAJOR ENVELOPE GLYCOPROTEIN OF LYMPHADENOPATHY-ASSOCIATED VIRUS", XP008052573 *
Chemical Abstracts Service (C A S); 19 September 1985 (1985-09-19), SCHNEIDER J, ET AL.: "A GLYCOPOLYPEPTIDE (GP 100) IS THE MAIN ANTIGEN DETECTED BY HTLV-III ANTISERUMS", XP008052570 *
Current Biotechnology Abstracts, 0310003226, Centocor unveils rDNS AIDS assay; faces FDA, 5 August 1985, US; Biotechnology Newswatch, vol. 5, issue 15, page 3 *
KALYANARAMAN V S, ET AL.: "ANTIBODIES TO THE CORE PROTEIN OF LYMPHADENOPATHY-ASSOCIATED VIRUS (LAV) IN PATIENTS WITH AIDS", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE, US, vol. 225, 20 July 1984 (1984-07-20), US, pages 321 - 323, XP008006409, ISSN: 0036-8075, DOI: 10.1126/science.6330889 *
MARSHALL D. J., DEGHENGHI R.: "A NEW DIRECT SYNTHESIS OF EQUILIN FROM EQUILENIN. POTASSIUM-AMMONIA REDUCTION OF SOME NON-CONJUGATED DOUBLE BONDS.", CANADIAN JOURNAL OF CHEMISTRY, NRC RESEARCH PRESS, CA, vol. 47., no. 17., 1 January 1969 (1969-01-01), CA, pages 3127 - 3131., XP000852571, ISSN: 0008-4042, DOI: 10.1139/v69-517 *
MUESING M A, ET AL.: "NUCLEIC ACID STRUCTURE AND EXPRESSION OF THE HUMAN AIDS/LXMPHADENOPATHY RETROVIRUS", NATURE, NATURE PUBLISHING GROUP, UNITED KINGDOM, vol. 313, no. 6002, 7 February 1985 (1985-02-07), United Kingdom, pages 450 - 458, XP008052558, ISSN: 0028-0836, DOI: 10.1038/313450a0 *
SCHUEPBACH J, ET AL.: "SEROLOGICAL ANALYSIS OF A SUBGROUP OF HUMAN T-LYMPHOTROPHIC RETROVIRUSES (HTLV-III) ASSOCIATED WITH AIDS", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE, US, vol. 224, 4 May 1984 (1984-05-04), US, pages 503 - 505, XP001154352, ISSN: 0036-8075, DOI: 10.1126/science.6200937 *
WAIN-HOBSON S., ET AL.: "NUCLEOTIDE SEQUENCE OF THE AIDS VIRUS, LAV.", CELL, CELL PRESS, US, vol. 40., no. 01., 1 January 1985 (1985-01-01), US, pages 09 - 17., XP000608742, ISSN: 0092-8674, DOI: 10.1016/0092-8674(85)90303-4 *
WEISS R A, ET AL.: "NEUTRALIZATION OF HUMAN T-LYMPHOTROPIC VIRUS TYPE III BY SERA OF AIDS AND AIDS-RISK PATIENTS", NATURE, NATURE PUBLISHING GROUP, UNITED KINGDOM, vol. 316, 4 July 1985 (1985-07-04), United Kingdom, pages 69 - 72, XP008052557, ISSN: 0028-0836, DOI: 10.1038/316069a0 *

Cited By (157)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5610035A (en) * 1983-12-05 1997-03-11 Institut Pasteur Centre National De La Recherche Scientific Methods for the preparation of hybridomas producing lymphadenopathy-associated virus (LAV) GP110-specific monoclonal antibodies and methods for the purification of GP110 employing said monoclonal antibodies
EP0552850A1 (fr) 1984-10-10 1993-07-28 Centocor, Inc. Clonage et expression d'ADN de HTLV-III
US7205101B1 (en) 1984-10-31 2007-04-17 Novartis Vaccines And Diagnostics, Inc. Human immunodeficiency virus (HIV) nucleotide sequences, recombinant polypeptides, and applications thereof
US6013432A (en) * 1984-10-31 2000-01-11 Chiron Corporation Immunoassay of HIV antibodies using recombinant or synthetic selected pol sequence
US5156949A (en) * 1984-10-31 1992-10-20 Chiron Corporation Immunoassays for antibody to human immunodeficiency virus using recombinant antigens
US7408053B1 (en) 1984-10-31 2008-08-05 Novartis Vaccines And Diagnostics, Inc. Recombinant DNA constructs for GAG polypeptides and polypeptides produced thereby
US7425428B1 (en) 1984-10-31 2008-09-16 Novartis Vaccines And Diagnostics, Inc. Recombinant DNA construct for HIV envelope polypeptides and polypeptides produced thereby
US7527925B1 (en) 1984-10-31 2009-05-05 Novartis Vaccines And Diagnostics, Inc. Purified pol DNA, a recombinant DNA construct for expression of HIV pol polypeptide sequences and a cell containing such construct
USRE41158E1 (en) * 1984-10-31 2010-03-02 Novartis Vaccines And Diagnostics, Inc. Human immunodeficiency virus (HIV) nucleotide sequences
US7273695B1 (en) 1984-10-31 2007-09-25 Novartis Vaccines And Diagnostics, Inc. HIV immunoassays using synthetic envelope polypeptides
US7285271B1 (en) 1984-10-31 2007-10-23 Novartis Vaccines And Diagnostics, Inc. Antigenic composition comprising an HIV gag or env polypeptide
US6531276B1 (en) 1984-10-31 2003-03-11 Chiron Corporation Methods for detecting human immunodeficiency virus nucleic acid
EP0201588A1 (fr) * 1984-11-09 1986-11-20 Harvard College Analyse de detection d'une infection par un virus lymphotrophique de cellules t humaines.
EP0201588A4 (fr) * 1984-11-09 1988-03-18 Harvard College Analyse de detection d'une infection par un virus lymphotrophique de cellules t humaines.
US5731142A (en) * 1984-11-09 1998-03-24 President And Fellows Of Harvard College Assay for detecting infection by HTLV-III
US6534285B1 (en) 1984-12-24 2003-03-18 Genentech, Inc. Molecularly cloned acquired immunodeficiency syndrome polypeptides and their methods of use
US5328835A (en) * 1985-04-08 1994-07-12 Bristol-Myers Squibb Company Expression of immunologically reactive HIV envelope proteins
US6077935A (en) * 1985-04-19 2000-06-20 The United States Of America As Represented By The Department Of Health And Human Services Acquired immune deficiency syndrome (AIDS) viral envelope protein and method of testing for AIDS
US5869233A (en) * 1985-04-19 1999-02-09 Crowl; Robert M. Acquired immune deficiency syndrome (AIDS) viral envelope protein and method of testing for AIDS
US5773210A (en) * 1985-04-19 1998-06-30 The United States Of America As Represented By The Department Of Health And Human Services Acquired immune deficiency syndrome (AIDS) viral envelope protein and method of testing for AIDS
US6485900B1 (en) 1985-04-29 2002-11-26 Bio-Rad Laboratories Synthetic antigen for the detection of AIDS-related disease
US6214539B1 (en) 1985-04-29 2001-04-10 Bio-Rad Laboratories Synthetic antigen the detection of aids-related disease
FR2593519A1 (fr) * 1985-09-25 1987-07-31 Oncogen Vaccin contre le syndrome immunodeficitaire acquis et intermediaires pour la preparation de ce vaccin
FR2587720A2 (fr) * 1985-09-25 1987-03-27 Oncogen Vaccin contre le syndrome immunodeficitaire acquis et intermediaires immunogeniques pour la preparation de ce vaccin et pour des dosages immunologiques de depistage de ce syndrome
EP0219106A3 (fr) * 1985-10-17 1989-02-08 F. Hoffmann-La Roche Ag Polypeptides induisant des anticorps contre le virus du SIDA
EP0219106A2 (fr) * 1985-10-17 1987-04-22 F. Hoffmann-La Roche Ag Polypeptides induisant des anticorps contre le virus du SIDA
EP0245362A1 (fr) * 1985-10-24 1987-11-19 Southwest Found Biomed Res Peptides synthetiques et leur utilisation pour le diagnostic et la vaccination contre le sida et son complexe associe.
EP0245362A4 (fr) * 1985-10-24 1990-04-10 Southwest Found Biomed Res Peptides synthetiques et leur utilisation pour le diagnostic et la vaccination contre le sida et son complexe associe.
US6979535B2 (en) 1986-01-22 2005-12-27 Institut Pasteur Human immunodeficiency virus type 2 (HIV-2) env polypeptide and diagnostic assays
US6514691B1 (en) 1986-01-22 2003-02-04 Institut Pasteur Peptides of human immunodeficiency virus type 2 (HIV-2), antibodies against peptides of HIV-2, and methods and kits for detecting HIV-2
EP0239425B1 (fr) * 1986-01-22 1989-11-02 Institut Pasteur Rétrovirus du type HIV-2 susceptible de provoquer le SIDA, et ses constituants antigéniques et nucléiques
US4839288A (en) * 1986-01-22 1989-06-13 Institut Pasteur Retrovirus capable of causing AIDS, antigens obtained from this retrovirus and corresponding antibodies and their application for diagnostic purposes
EP0231914A2 (fr) * 1986-02-03 1987-08-12 F. Hoffmann-La Roche Ag Peptides d'enveloppe de HTLV-III
EP0233045A2 (fr) * 1986-02-03 1987-08-19 Cambridge Biotech Corporation Peptides pour le diagnostic des anticorps HTLV-III, ainsi que leur préparation et leur utilisation
EP0231914A3 (en) * 1986-02-03 1989-11-15 F. Hoffmann-La Roche & Co. Aktiengesellschaft Htlv-iii envelope peptides
EP0233045A3 (en) * 1986-02-03 1989-05-03 Cambridge Bioscience Corporation Peptides for the diagnose of htlv-iii antibodies, their preparation and use
US6130314A (en) * 1986-03-26 2000-10-10 Genetic Systems Corporation Synthetic antigen for the detection of AIDS-related disease
EP0269712A4 (fr) * 1986-06-12 1990-06-26 Biogen Nv Peptides impliques dans la pathogenese d'une infection du type hiv.
US4943627A (en) * 1986-06-12 1990-07-24 Biogen, Inc. Peptides involved in the pathogenesis of HIV infection
US5017688A (en) * 1986-06-12 1991-05-21 Biogen, Inc. Peptides involved in the pathogenesis of HIV infection
EP0269712A1 (fr) * 1986-06-12 1988-06-08 Biogen, Inc. Peptides impliques dans la pathogenese d'une infection du type hiv
FR2601457A1 (fr) * 1986-07-08 1988-01-15 Bio Rad Laboratories Procede de differenciation des etats pathologiques dans des essais utilisant des anticorps anti-sida
EP0255190A3 (fr) * 1986-08-01 1990-08-29 Repligen Corporation Polypeptides recombinants et leurs applications, ainsi qu'essai pour le virus du SIDA
EP0255190A2 (fr) * 1986-08-01 1988-02-03 Repligen Corporation Polypeptides recombinants et leurs applications, ainsi qu'essai pour le virus du SIDA
FR2603107A1 (fr) * 1986-08-20 1988-02-26 Genetic Systems Corp Compositions, vaccin et anticorps monoclonaux utiles pour le traitement des affections par le virus hiv et procedes de production de ces anticorps et de diagnostic de la presence de ce virus
US5166050A (en) * 1986-08-20 1992-11-24 Bristol-Myers Squibb Company Monoclonal antibodies and peptides useful in treating and diagnosing HIV infections
DE3727703A1 (de) * 1986-08-20 1988-05-05 Genetic Systems Corp Monoklonale antikoerper und peptide, welche zur behandlung und diagnose von hiv-infektionen brauchbar sind
BE1000811A4 (fr) * 1986-08-20 1989-04-11 Genetic Systems Corp Anticorps monoclonaux, peptides et compositions les contenant, destinees au diagnostic et au traitement des infections par le virus hiv.
GB2196634B (en) * 1986-08-20 1991-05-15 Genetic Systems Corp Monoclonal antibodies to hiv and related peptides
EP0260714A2 (fr) * 1986-09-19 1988-03-23 Oncogen Limited Partnership Utilisation de lymphocytes T actives dans la préparation d'un médicament pour le traitement du SIDA
EP0260714A3 (en) * 1986-09-19 1988-08-24 Oncogen The use of activated t-lymphocytes for preparing a pharmaceutical composition for the treatment of aids
EP0267802A3 (fr) * 1986-11-14 1991-03-06 Genetic Systems Corporation Antigène synthétique pour la détection de maladie de SIDA et maladies s'y rapportant
EP0267802A2 (fr) * 1986-11-14 1988-05-18 Genetic Systems Corporation Antigène synthétique pour la détection de maladie de SIDA et maladies s'y rapportant
EP0283327A2 (fr) * 1987-01-16 1988-09-21 Institut Pasteur Peptides ayant des propriétés immunologiques de HIV-2
EP0283327A3 (fr) * 1987-01-16 1989-01-04 Institut Pasteur Peptides ayant des propriétés immunologiques de HIV-2
WO1988005440A1 (fr) * 1987-01-16 1988-07-28 Institut Pasteur Peptides ayant des proprietes immunologiques 2-hiv-2
EP0278148A3 (en) * 1987-02-10 1990-06-06 United Biomedical Inc. Peptide composition and method for the detection of antibodies to htlv-iii
EP0278148A2 (fr) * 1987-02-10 1988-08-17 United Biomedical, Inc. Composition peptidique et procédé pour la détection d'anticorps contre HTLV-III
FR2610632A1 (fr) * 1987-02-11 1988-08-12 Pasteur Institut Peptides caracteristiques des retrovirus d'immunodeficience humaine (virus hiv) leurs applications au diagnostic des infections dues a certains de ces virus et, le cas echeant, a la vaccination contre le sida
EP0279688A3 (fr) * 1987-02-20 1989-09-13 Genentech, Inc. Méthodes et compositions pour l'utilisation de polypeptides env et anticorps anti-env de HIV
EP0284587A2 (fr) * 1987-03-27 1988-09-28 Syntello Ab Antigènes peptides synthétiques pour la détection d'infections de HIV-1
EP0284587A3 (fr) * 1987-03-27 1990-11-22 Syntello Ab Antigènes peptides synthétiques pour la détection d'infections de HIV-1
FR2614025A1 (fr) * 1987-04-15 1988-10-21 Pasteur Institut Peptides susceptibles d'etre reconnus par des anticorps induits contre des retrovirus d'immunodeficience humaine (virus hiv) leurs applications au diagnostic des infections dues a certains de ces virus et, le cas echeant, a la vaccination contre le sida
WO1988008429A1 (fr) * 1987-04-24 1988-11-03 Biogen N.V. Procedes et compositions immunotherapeutiques
WO1988009181A3 (fr) * 1987-05-29 1989-02-09 Tanox Biosystems Inc Anticorps monoclonaux neutralisant le hiv-1
WO1988009181A2 (fr) * 1987-05-29 1988-12-01 Tanox Biosystems, Inc. Anticorps monoclonaux neutralisant le hiv-1
US6657050B1 (en) 1987-05-29 2003-12-02 Tanox, Inc. Chimeric viral-neutralizing immunoglobulins
US5834599A (en) * 1987-05-29 1998-11-10 Tanox Biosystems, Inc. Immunoconjugates which neutralize HIV-1 infection
US5981278A (en) * 1987-05-29 1999-11-09 Tanox, Inc. Chimeric monoclonal antibodies which neutralize HIV-1 infection and their applications in therapy and prevention for AIDS
WO1988009339A1 (fr) * 1987-05-29 1988-12-01 Labsystems Oy Polypeptide hiv, sa preparation et utilisation pour la detection d'anticorps hiv
WO1988010267A1 (fr) * 1987-06-24 1988-12-29 Proteus Biotechnology Limited Peptides synthetiques apparentes a des proteines hiv-env
EP0298633A2 (fr) * 1987-06-24 1989-01-11 Proteus Molecular Design Limited Polypeptides synthétiques
EP0298633A3 (fr) * 1987-06-24 1989-04-26 Proteus Molecular Design Limited Polypeptides synthétiques
EP0311219A1 (fr) * 1987-10-09 1989-04-12 Stichting Centraal Diergeneeskundig Instituut Oligopeptide et leur application pour le diagnostic et la vaccination relatifs au SIDA et â l'ARC
WO1989003391A1 (fr) * 1987-10-09 1989-04-20 Stichting Centraal Diergeneeskundig Instituut Oligopeptides et leur utilisation a des fins de diagnostic et de vaccination en rapport avec le sida et l'arc
EP0317804A3 (en) * 1987-11-24 1990-09-12 Abbott Laboratories Hiv peptides and methods for detection of hiv
EP0317804A2 (fr) * 1987-11-24 1989-05-31 Abbott Laboratories Peptides de VIH et méthodes de détection de VIH
US7393949B1 (en) 1987-12-24 2008-07-01 Novartis Vaccines And Diagnostics, Inc. Human immunodeficiency virus (HIV) nucleotide sequences
US7442525B1 (en) 1987-12-24 2008-10-28 Novartis Vaccines And Diagnostics, Inc. Method for expressing HIV polypeptides
WO1989006240A1 (fr) * 1987-12-30 1989-07-13 Jonas Blomberg PEPTIDE CORRESPONDANT AU VIH-env 583-599, ET SES ANALOGUES, AINSI QUE LES APPLICATIONS DES PEPTIDES
EP0400076A4 (en) * 1988-01-26 1991-11-13 Us Health A synthetic antigen evoking anti-hiv response
EP0400076A1 (fr) * 1988-01-26 1990-12-05 Us Health Antigene synthetique suscitant une reaction anti-vih.
US5976541A (en) * 1988-01-26 1999-11-02 The United States Of America As Represented By The Department Of Health And Human Services Potent peptide for stimulation of cytotoxic T lymphocytes specific for the HIV-1 envelope
US5820865A (en) * 1988-01-26 1998-10-13 The United States Of America As Represented By The Department Of Health And Human Services Method to induce cytotoxic T Lymphocytes specific for a broad array of HIV-1 isolates using hybrid synthetic peptides
EP0328403A2 (fr) * 1988-02-12 1989-08-16 United Biomedical Inc. Peptides synthétiques relatifs à la protéine HIV-GP120-env. et leur application
EP0328403A3 (fr) * 1988-02-12 1991-09-25 United Biomedical Inc. Peptides synthétiques relatifs à la protéine HIV-GP120-env. et leur application
US5763160A (en) * 1988-02-12 1998-06-09 United Biomedical, Inc. Synthetic peptides and process of using same for the detection of antibodies to human immunodeficiency virus (HIV) gp120 envelope protein, diagnosis of AIDS and pre-AIDS conditions and as vaccines
AU632475B2 (en) * 1988-04-26 1993-01-07 Du Pont Merck Pharmaceutical Company, The Human immunodeficiency virus (hiv) env-coded peptide capable of eliciting hiv-inhibiting antibodies in mammals
EP0339504A2 (fr) * 1988-04-26 1989-11-02 The Du Pont Merck Pharmaceutical Company Virus d'immunodéficience humaine (HIV) peptide env-codé capable de provoquer les anticorps inhibiteurs du HIV dans les mammifères
EP0339504A3 (fr) * 1988-04-26 1990-09-12 The Du Pont Merck Pharmaceutical Company Virus d'immunodéficience humaine (HIV) peptide env-codé capable de provoquer les anticorps inhibiteurs du HIV dans les mammifères
US5562905A (en) * 1988-04-26 1996-10-08 E. I. Du Pont De Nemours And Company Human immunodeficiency virus (hiv) env-coded peptide capable of eliciting hiv-inhibiting antibodies in mammals
FR2632310A1 (fr) * 1988-06-06 1989-12-08 Pasteur Institut Peptides ayant des proprietes protectrices d'un virus pathogene du type hiv dans des cellules sensibles
WO1989012066A1 (fr) * 1988-06-06 1989-12-14 Institut Pasteur Peptides ayant des proprietes protectrices d'un virus pathogene du type hiv dans des cellules sensibles
US5858647A (en) * 1988-06-09 1999-01-12 Innogenetics N.V. Methods for detecting antibodies against HIV-3 retrovirus and its use!
US6265200B1 (en) 1988-06-09 2001-07-24 Innogenetics N.V. HIV-3 retrovirus and its use
US6013484A (en) * 1988-06-09 2000-01-11 Innogenetics N.V. HIV-3 retrovirus and its use
US5304466A (en) * 1988-06-09 1994-04-19 Innogenetics N.V. HIV-3 retrovirus and its use
EP0345375A1 (fr) * 1988-06-09 1989-12-13 N.V. Innogenetics S.A. Rétrovirus HIV-3 et son utilisation
US5795743A (en) * 1988-06-09 1998-08-18 Innogenetics N.V. HIV-3 retrovirus antigen compositions
WO1989012094A1 (fr) * 1988-06-09 1989-12-14 Innogenetics N.V. Retrovirus hiv-3 et son utilisation
US5567603A (en) * 1988-06-09 1996-10-22 Innogenetics N.V. HIV-3 retrovirus and its use
US5683701A (en) * 1988-06-10 1997-11-04 United Biomedical, Inc. Peptide fragments of HIV
US5185147A (en) * 1988-08-19 1993-02-09 Cellular Products, Inc. Short polypeptide sequences useful in the production and detection of antibodies against human immunodeficiency virus
EP0418347A4 (en) * 1989-02-28 1994-12-14 Univ New York Human monoclonal antibodies to human immunodeficiency virus
EP0418347A1 (fr) * 1989-02-28 1991-03-27 New York University Anticorps monoclonaux humains contre le virus d'immunodeficience humaine
US5731189A (en) * 1989-02-28 1998-03-24 New York University Human monoclonal antibodies to human immunodeficiency virus
WO1990013564A1 (fr) * 1989-05-03 1990-11-15 Connaught Laboratories Limited Peptides synthetiques pour vaccin contre l'hiv-1
WO1990015158A1 (fr) * 1989-06-02 1990-12-13 Institut Pasteur Sequences oligonucleotidiques pour l'amplification du genome des retrovirus du type hiv-2 et siv, et leurs applications au diagnostic in vitro des infections dues a ces virus
EP1715064A1 (fr) * 1989-06-02 2006-10-25 Institut Pasteur Séquences nucléotidiques issues du génome des rétrovirus du type HIV-1, HIV-2 et SIV, et leurs applications notamment pour l'amplification des génomes de ces rétrovirus et pour le diagnostic in vitro des infections dûes à ces virus
EP0404625A3 (fr) * 1989-06-02 1991-01-16 Institut Pasteur Séquences oligonucléotidiques pour l'amplification du génome des rétrovirus du type HIV-2 et SIV, et leurs applications au diagnostic in-vitro des infections dûes à ces virus
US7777020B2 (en) 1989-06-02 2010-08-17 Institut Pasteur Nucleotide sequences derived from the env gene of HIV-1
EP0806484B1 (fr) * 1989-06-02 2006-04-12 Institut Pasteur Synthèse de protéines ou de polypeptides codés par une séquence nucléotidique de HIV-1, HIV-2 ou SIV.
US6194142B1 (en) 1989-06-02 2001-02-27 Institut Pasteur Nucleotide sequences derived from the genome of retroviruses of the HIV-1, HIV-2, and SIV type, and their uses in particular for the amplification of the genomes of these retroviruses and for the in vitro diagnosis of the diseases due to these viruses
FR2647810A1 (fr) * 1989-06-02 1990-12-07 Pasteur Institut Amorces oligonucleotidiques pour l'amplification du genome des retrovirus du type hiv-2 et siv, et leurs applications au diagnostic in vitro des infections dues a ces virus
US5688637A (en) * 1989-06-02 1997-11-18 Institut Pasteur Nucleotide sequences derived from the genome of retroviruses of the HIV-1, HIV-2 and SIV type, and their uses in particular for the amplification of the genomes of these retroviruses and for the in vitro diagnosis of the disease due to these viruses
EP0806484A2 (fr) * 1989-06-02 1997-11-12 Institut Pasteur Séquences nucléotidiques issues du genome des rétrovirus du type hiv-1, hiv-2 et siv, et leurs applications notamment pour l'amplification des genomes de ces rétrovirus et pour le diagnostic in vitro des infections dues à ces virus
US6020123A (en) * 1989-06-02 2000-02-01 Institut Pasteur Oligonucleotide sequences for the amplification of the genome of the retroviruses of the HIV-2 and SIV type, and their uses for in vitro diagnosis of the infections due to these viruses
EP0404625A2 (fr) * 1989-06-02 1990-12-27 Institut Pasteur Séquences oligonucléotidiques pour l'amplification du génome des rétrovirus du type HIV-2 et SIV, et leurs applications au diagnostic in-vitro des infections dûes à ces virus
US7759477B2 (en) 1989-06-02 2010-07-20 Institut Pasteur HIV-1, HIV-2, and SIV pol nucleotide fragments
US6165710A (en) * 1989-10-23 2000-12-26 Robinson; James E. Method for immobilizing viral glycoproteins for use in solid-phase immunoassays
US6248574B1 (en) 1989-12-13 2001-06-19 Avigdor Shaffermann Polypeptides selectively reactive with antibodies against human immunodeficiency virus and vaccines comprising the polypeptides
WO1991009872A3 (fr) * 1989-12-13 1992-04-02 Univax Biolog Inc Polypeptides selectivement reactifs avec des anticorps contre le virus d'immunodeficience humaine et vaccins comprenant les polypeptides
US5700469A (en) * 1990-01-05 1997-12-23 Medical Research Council HIV-1 core protein fragments
GB2255093B (en) * 1990-01-05 1994-09-28 Medical Res Council HIV-1 core protein fragments
US5480967A (en) * 1990-01-05 1996-01-02 United Biomedical, Inc. HIV-1 core protein fragments
WO1991009869A1 (fr) * 1990-01-05 1991-07-11 Medical Research Council Fragments de la proteine du noyau de vih-1
GB2255093A (en) * 1990-01-05 1992-10-28 Medical Res Council Hiv-1 core protein fragments
WO1991013360A1 (fr) * 1990-02-20 1991-09-05 Replico Medical Aktiebolag NOUVEAUX PEPTIDES D'HIV p24, ANTIGENES DIAGNOSTIQUES ET METHODE D'IMMUNO-ANALYSE DISCRIMINANTE
EP0494317A1 (fr) 1990-06-15 1992-07-15 Innogenetics N.V. Le rétrovirus SIV cpz-ant et ses applications
EP0494317B2 (fr) † 1990-06-15 2000-12-27 Innogenetics N.V. Le rétrovirus SIV cpz-ant et ses applications
US5346989A (en) * 1990-08-22 1994-09-13 Syntello Vaccine Development Kb Peptides for use in induction of T cell activation against HIV-1
US5589175A (en) * 1990-09-27 1996-12-31 Syntello Vaccine Development Kb Peptides for induction of neutralizing antibodies against human immunodeficiency virus
US5840313A (en) * 1990-09-27 1998-11-24 Syntello Vaccine Development Kb Peptides for use in vaccination and induction of neutralizing antibodies against human immunodeficiency virus
WO1992006199A2 (fr) * 1990-09-27 1992-04-16 Institut Pasteur Peptides inducteurs d'anticorps inhibant des retrovirus du type hiv et anticorps diriges contre ces peptides
WO1992006199A3 (fr) * 1990-09-27 1992-05-29 Pasteur Institut Peptides inducteurs d'anticorps inhibant des retrovirus du type hiv et anticorps diriges contre ces peptides
WO1992005800A1 (fr) * 1990-09-27 1992-04-16 Syntello Vaccin Development Kb Peptides destines a etre utilises dans la vaccination et dans l'induction d'anticorps neutralisants pour lutter contre le virus d'immunodeficience humaine
US5871746A (en) * 1990-12-18 1999-02-16 Institut National De La Sainte Et De La Recherche Medicale (Inserm) Cytotoxic T lymphocyte-inducing lipopeptides and use as vaccines
EP0495465A2 (fr) * 1991-01-15 1992-07-22 Coulston International Corporation Essai immuno-enzymatique pour détecter des anticorps virales
EP0495465A3 (en) * 1991-01-15 1992-12-16 Coulston International Corporation Immuno-enzymatic test for the detection of viral antibody
WO1992021377A1 (fr) * 1991-06-03 1992-12-10 Syntello Inc. Peptides a utiliser pour induire l'activation de lymphocytes t contre le vih-1
FR2677364A1 (fr) * 1991-06-05 1992-12-11 Pasteur Institut Sequences peptidiques de la glycoproteine externe d'enveloppe du retrovirus hiv-1.
US7022814B1 (en) 1992-01-21 2006-04-04 Institut Pasteur And Institut National De La Sante Et De La Recherche Medicale Nucleotide sequences derived from the genome of retroviruses of the HIV-1, HIV-2 and SIV type, and their uses in particular for the amplification of the genomes of these retroviruses and for the in vitro diagnosis of the diseases due to these viruses
US7988974B2 (en) 1993-06-07 2011-08-02 Duke University Antifusogenic proteins comprising human immunodeficiency virus type 1 (HIV-1) gp41 DP-178 polypeptide variants and a macromolecular carrier
US7794725B1 (en) 1993-06-07 2010-09-14 Trimeris, Inc. Isolated peptides derived from human immunodeficiency virus types 1 and 2 containing fusion inhibitory domains
US7122190B2 (en) 1993-06-07 2006-10-17 Duke University Fusion proteins comprising DP-178 and other viral fusion inhibitor peptides useful for treating aids
US6335158B2 (en) 1994-02-23 2002-01-01 Dade Behring Marburg Gmbh Methodologies for the detection of human immunodeficiency virus nucleic acids employing oligonucleotide primer derived from the HIV-1 MVP5180/91 genome
US5830634A (en) * 1994-02-23 1998-11-03 Dade Behring Marburg Gmbh Peptides derived from a retrovirus of the HIV group and their use
US6869608B2 (en) 1994-02-23 2005-03-22 Dade Behring Marburg Gmbh Peptides derived from a retrovirus of the HIV group and their use
US7803524B2 (en) 1994-02-23 2010-09-28 Siemens Healthcare Diagnostics Products Gmbh Antigenic HIV gp41 chimeric polypeptides comprising the MVP5180/91 epitope SKGKLIS
WO1998026075A1 (fr) * 1996-12-09 1998-06-18 Institut National De La Sante Et De La Recherche Medicale - Inserm Souches de vih-1 non-m non-o, fragments et applications
US7534877B2 (en) 1996-12-09 2009-05-19 Institute National De La Sante Et De La Recherche Medicale-Inserm Non-M, non-O HIV-1 strains, fragments and uses
FR2756843A1 (fr) * 1996-12-09 1998-06-12 Inst Nat Sante Rech Med Souches de vih-1 non-m non-o, fragments et applications
US6509018B1 (en) 1996-12-09 2003-01-21 Institute National De La Sante Et De La Recherche Medicale-Inserm Non-M non-O HIV strains, fragments and uses
CN1244896B (zh) * 1996-12-09 2011-06-22 国家健康科学研究所 非-m、非-o hiv-1毒株、片段及应用
US7030234B2 (en) 1996-12-09 2006-04-18 Institute National De La Sante Et De La Recherche Medicale-Inserm Non-M, non-O HIV-1 strains, fragments and uses
US8227185B2 (en) 1996-12-09 2012-07-24 Institute National de la Sante et de la Recherche Medical-Inserm Non-M, non-O HIV-1 strains, fragments and uses
EP1307130A4 (fr) * 2000-02-04 2005-01-12 Beth Israel Hospital Vaccin contre le virus de l'immunodeficience humaine

Also Published As

Publication number Publication date
HK1053662A1 (en) 2003-10-31
JP2777115B2 (ja) 1998-07-16
DE3587181T2 (de) 1993-06-24
HK1050215A1 (en) 2003-06-13
DE3587512D1 (de) 1993-09-09
EP1279678A1 (fr) 2003-01-29
JP2761376B2 (ja) 1998-06-04
AU5061785A (en) 1986-05-02
ES548048A0 (es) 1987-05-01
EP0387915B1 (fr) 1993-03-10
JPH09178751A (ja) 1997-07-11
EP0462627B1 (fr) 2003-09-17
DE3587181D1 (de) 1993-04-15
ES8801319A1 (es) 1987-12-16
ATE92502T1 (de) 1993-08-15
DK284986D0 (da) 1986-06-18
EP0462627A1 (fr) 1991-12-27
KR880700076A (ko) 1988-02-15
ATE86636T1 (de) 1993-03-15
DE3588251D1 (de) 2005-02-03
HK1050215B (zh) 2005-05-20
IE852587L (en) 1986-04-18
AU603543B2 (en) 1990-11-22
ATE373010T1 (de) 2007-09-15
DE3588254T2 (de) 2008-06-26
DE122005000039I1 (de) 2006-02-23
DK174910B1 (da) 2004-02-16
EP0387914A1 (fr) 1990-09-19
DE3587512T2 (de) 1993-12-02
JP2752329B2 (ja) 1998-05-18
NZ230372A (en) 1994-02-25
JPH09118689A (ja) 1997-05-06
JPH09132594A (ja) 1997-05-20
ATE250083T1 (de) 2003-10-15
ES557357A0 (es) 1987-12-16
ATE286132T1 (de) 2005-01-15
JPH07309779A (ja) 1995-11-28
EP0387914B1 (fr) 1993-08-04
EP0201540A1 (fr) 1986-11-20
PT81338B (pt) 1987-11-11
DE3588251T2 (de) 2006-01-12
EP0462627B2 (fr) 2011-04-27
DE3583293D1 (de) 1991-07-25
PT81338A (en) 1985-11-01
EP1279678B1 (fr) 2007-09-12
CA1341620C (fr) 2011-08-23
GR852522B (fr) 1986-02-17
DE3588254D1 (de) 2007-10-25
DK35593A (da) 1993-03-26
DK35593D0 (da) 1993-03-26
DE3588248D1 (de) 2003-10-23
DK284986A (da) 1986-08-14
KR930000189B1 (ko) 1993-01-11
EP0201540B2 (fr) 2001-10-31
JP2971034B2 (ja) 1999-11-02
ATE64601T1 (de) 1991-07-15
ES8801318A1 (es) 1987-12-16
ES8705522A1 (es) 1987-05-01
EP0201540B1 (fr) 1991-06-19
ES557358A0 (es) 1987-12-16
EP0387915A1 (fr) 1990-09-19
DK172814B1 (da) 1999-07-19
DE3588248T2 (de) 2004-07-01
IE64006B1 (en) 1995-06-28

Similar Documents

Publication Publication Date Title
EP0387915B1 (fr) Antigènes F du virus humain d'immunodéficience, et leurs applications
US5030714A (en) Variant of LAV viruses
ES2293643T5 (es) Secuencias nucleotídicas de antígenos retrovíricos vih-1 del grupo (o subgrupo) o.
US5843638A (en) Nucleic acids and pepties of human immunodeficiency virus type-1 (HIV-1).
US7029679B2 (en) Variant of LAV viruses
US6635752B2 (en) Variant of LAV viruses
US5019510A (en) Isolation, molecular cloning and sequencing of an HIV-1 isolate from a Gabonese donor
JP2609448B2 (ja) リンパ節症及び後天性免疫不全症候群のウイルスのエンベロープ抗原
EP1231271B1 (fr) Fragments d'ADN du gène GAG de LAV
CA1340875C (fr) Variants des virus lav, leur adn et fractions proteiques et leur utilis ation, en particulier a des fins diagnostiques et dans la preparation de compositions immunogenes

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU BR DK JP KR

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CF CG CH CM DE FR GA GB IT LU ML MR NL SE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 1985905513

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1985905513

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1985905513

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载